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ABSTRACT 
    Studies have demonstrated that under conditions of chronic metabolic stress, GLUT1-
mediated sugar transport is upregulated at the blood-brain barrier by a number of 
mechanisms. Although acute metabolic stress has also been shown to increase GLUT1-
mediated transport, the mechanisms underlying this regulation remain unclear. This work 
attempts to explain how GLUT1-mediated sugar uptake is increased during acute 
metabolic stress, as well as explore the factors involved in this modulation of sugar 
transport in blood-brain barrier endothelial cells. Glucose depletion, KCN and FCCP 
were applied to brain microvascular endothelial cell line bEnd.3 in order to induce acute 
metabolic stress by ATP depletion. Kinetic sugar uptake measurements in combination 
with qPCR, whole cell lysate western blots, and cell-surface biotinylation were employed 
to probe for changes in GLUT1-mediated sugar uptake, GLUT1 expression levels, and 
GLUT1 localization during metabolic stress. Finally, the role of AMP-activated kinase 
(AMPK) in the bEnd.3 cell response to acute stress was examined using the specific 
AMPK activator AICAR and inhibitor Compound C. 
    The data presented in this thesis supports the following two conclusions: 1. GLUT1-
mediated sugar transport in bEnd.3 cells during acute metabolic stress is increased 3-7 
fold due to translocation of intracellular GLUT1 to the plasma membrane, with no change 
in expression of total GLUT1 protein, and 2. AMPK plays a direct role in modulating 
increases in GLUT1-mediated sugar transport in bEnd.3 cells during acute metabolic 
stress by regulating trafficking of GLUT1 to the plasma membrane 
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CHAPTER I 
 INTRODUCTION AND LITERATURE REVIEW 
The Brain 
    In mammals, the brain is responsible for integrating and maintaining a variety of 
systemic processes that are required to sustain the life of the organism. Whether 
coordinating basic organ function, regulating hormone levels, integrating external stimuli, 
or executing higher order behavioral responses in order to promote survival (1-6), healthy 
brain function is essential in order to maintain system-wide bodily homeostasis in all 
living mammals. Although the majority of the details of exactly how the brain works 
remain elusive, modern research is making progress in uncovering how the brain operates 
and promotes its own survival. One of the most basic, yet most important requirements 
for proper brain function is a constant supply of energy. By attempting to understand how 
the brain is able to manage its energy needs, it may be possible to gain more insight into 
how different areas of the brain operate locally, as well as how the brain communicate 
with other systems on a global scale in order to maintain a healthy mammalian system. 
Brain Metabolism 
    The brain primarily uses glucose as the preferred substrate for its energetic needs (7-
10). It has been stated that although the brain only accounts for a small percentage of 
total body mass (approximately 2%), it requires 25% of the body’s glucose supply in 
order to maintain function (11). Glucose consumption by the brain occurs in both neurons 
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and astrocytes, and appears to be a highly complex process (9,11,12). The supply of 
glucose from the blood is thought to barely meet the brain’s demand for energy under 
normal conditions (13); therefore it is important that the brain be able to control not only 
its metabolism, but access to a steady supply of glucose. In fact, it has been shown that 
increased activity in the brain is often met with increased blood flow to the active area, 
presumably to ensure the supply of glucose is sufficient to support increased brain 
function (14-16). 
    Although originally it was thought that direct oxidative phosphorylation of glucose 
was the preferred means of generating energy in neurons and astrocytes (7,8), there have 
been a number of studies that have shown that this is not always the case. The presence of 
monocarboxylate transporters in brain cells is well documented (12,17), and studies show 
increased consumption of lactate is used for energy generation in both neurons and 
astrocytes (18-21). The picture of brain metabolism becomes more complex upon 
considering the proposal that release of neuronal glutamate increases lactate production 
by astrocyte glycolysis. This lactate is then exported and taken up by active neurons for 
energy production in a process called the astrocyte to neuron lactate shuttle (22). To even 
further complicate the issue, a conflicting model has also been proposed where neuronal 
lactate produced by both basal and stimulated metabolism is shuttled into astrocytes for 
energy consumption in a process named the neuron to astrocyte lactate shuttle (23). 
    While there is currently no consensus on the precise model of integrated brain 
metabolism, what is fundamentally clear is that glucose is the essential substrate of brain 
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energy production, regardless of which glycolytic products are favored by brain cells. 
Neurons contain no appreciable stores of glycogen, and astrocytes contain a limited 
amount of glycogen at any given time, certainly not enough to sustain long-term brain 
function. Therefore, a steady supply of glucose must be maintained at all times. In order 
for the brain to utilize glucose, it must have access to it from the circulating bloodstream. 
While most mammalian organ systems allow for free exchange of nutrients between 
blood and tissue, glucose destined for the brain must overcome a significant hurdle before 
utilization: the blood-brain barrier. 
The Blood-Brain Barrier 
    The blood-brain barrier is a structure formed by endothelial cells that line the blood 
vessels throughout the majority of the brain (24). While endothelial cells are a key 
structural component of all blood vessels throughout the circulatory system, there are 
stark differences between endothelial cells comprising the blood-brain barrier (and other 
blood tissue barriers) and those of the peripheral circulatory system. First, blood-brain 
barrier endothelial cells contain significantly more mitochondria than peripheral 
endothelial cells (25). Second, it has also been shown that blood-brain barrier capillary 
walls are approximately 40% thinner than those of the peripheral endothelium (24). 
Finally, in most cases, the endothelium that lines the inside of blood vessels in the 
peripheral circulatory system is patterned with fenestrations, or gaps, between the 
interconnected cells. These fenestrations allow free diffusion of circulating nutrients 
between blood and surrounding tissues (26). However, the endothelial cells of the blood-
brain barrier are joined together by tight junctions (27,28), thus denying most large, 
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charged, and polar molecules, such as proteins (29), ions (30-32), and sugars (33-35), free 
passage from the bloodstream into the brain.  
    While the structure of the blood-brain barrier protects the delicate neurons of the brain 
from damage from a variety of toxic agents and pathogens, it also imposes a major hurdle 
to delivery of essential nutrients to the brain that are required for proper function, 
especially its primary energetic substrate, glucose (7,8,10). Since glucose cannot freely 
diffuse into the brain at a rate sufficient to meet energy demand, its movement across the 
blood-brain barrier, as with other nutrients, requires specialized carrier proteins (33-38), 
which must be present on both the luminal (blood-facing) and abluminal (brain-facing) 
membranes of the endothelial cell in order to efficiently deliver substrate to brain cells. 
The primary carrier protein responsible for glucose uptake across the blood-brain barrier 
has been identified as the facilitative glucose transport protein SLC2A1, or GLUT1 (39).  
Facilitative Transporters 
    Diffusion of molecules across the plasma membrane can be classified as either passive 
or active. Passive diffusion can be mediated by pores, channels, and carrier proteins (or 
transporters). Pores present simultaneous substrate binding sites on the inside and outside 
of the cell, and facilitate selective diffusion of molecules in a single-file motion through 
the protein down a concentration gradient. The water pore aquaporin is an example of a 
pore protein (40). Channels mediate the selective passage of ions across the plasma 
membrane down their electrochemical gradient. Unlike pores, channels are regulated by a 
number of factors such as membrane potential, ion concentration, and second messenger 
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molecules. Channels are often gated by a C-terminal portion of the protein which allows 
for the blocking of the channel once a certain threshold is reached. An example of this 
phenomenon is seen in voltage gated Kv K+ channels, which are responsible for 
modulating muscle contractions, especially in the heart (41). Neither pores nor channels 
require the direct use of energy to mediate substrate transport. The free energy driving net 
transport comes from the electrochemical gradient of the transported substrate. 
    Carrier proteins differ from pores and channels in a number of ways. First, carriers 
have been proposed to present a single substrate binding site on one side of the plasma 
membrane at a time, not simultaneously at both sides of the membrane like pores and 
channels (42,43). Second, upon binding substrate, carrier proteins undergo a 
conformational change which translocates substrate through the protein and across the 
plasma membrane, whereas pores and channels remain relatively fixed in the membrane 
(42). Finally, carriers can facilitate either passive or active transport of molecules, while 
pores and channels are strictly passive transport proteins.  Passive carriers such as 
GLUT1 demonstrate selectivity of substrate like pores and channels, and move molecules 
down their concentration gradient without energy expenditure (42). Active carriers fall 
into one of two categories, primary and secondary. Primary active carriers require ATP 
hydrolysis to induce a conformational change in the protein and allow transport a 
substrate against its concentration gradient. A good example of an active carrier is the 
Na+K+ATPase, which requires ATP to pump three sodium molecules out of the cell, at 
the same time importing two potassium molecules (44). Secondary active carriers do not 
require ATP hydrolysis, and can be divided into two sub-groups: antiporters and 
6 
 
symporters. Antiporters catalyze active transport by exchanging one molecule down its 
concentration gradient for another against its concentration gradient via conformational 
change of the protein. The NCX sodium calcium exchanger proteins, which import three 
sodium ions for every calcium ion exported out of the cell, are classic antiporters (45). 
Symporters catalyze the co-transport of two molecules in the same direction by using the 
energy of an electrochemical gradient of one of the molecules to drive the transport of 
another molecule against its concentration gradient. An example of a symport protein is 
the SGLT family of glucose transporters, which mediate glucose reabsorption in the 
kidney by using the energy of transporting sodium down its concentration gradient to co-
transport and take up glucose into the cell, where concentrations are high (46). 
     In order to understand the mechanisms of carrier mediated transport, it is important to 
examine some of the structural characteristics that define each class of proteins. The 
human facilitative glucose transport family of proteins contains fourteen members, each 
of which differs slightly in structure and function. However, there are key structural 
similarities between the members that help define the family and give some insight into 
the functional role each carrier plays in the body. 
The GLUT Family of Facilitative Transporters 
    GLUT1 is a member of the major facilitator superfamily (MFS) of carrier proteins, one 
of the largest membrane protein families found in living organisms (47,48). The MFS 
superfamily currently consists of 29 established families of transport proteins, including 
sugar, ion, and drug transporters, hexose proton symporters, and sugar ion symporters 
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found ubiquitously in all species including bacteria, plants, and mammals (49). To date, 
only three of the over 5,000 MFS superfamily members have been crystallized: the 
glycerol-3-phosphate transporter GlpT (50), the lactose permease LacY (51), and the 
multi-drug transporter EmrD (52), all from Escherichia coli. In addition, the structure of  
the oxalate-formate exchange protein OxlT from Oxalobacter formigenes has been 
visualized by cryo-electron microscopy, but not crystallized (53). While these proteins 
may provide some general structural insights into the organization of MFS superfamily 
proteins, the lack of sequence identity between members makes drawing sweeping 
conclusions about structure difficult. As a result, many of the properties of protein 
structure, function, and substrate binding for the majority of MFS members have yet to be 
elucidated. A subset of the MFS superfamily, the facilitative sugar transporter (or GLUT) 
family of proteins, currently contains 14 identified members in mammals, all members of 
the SLC2A (Solute Linked Carrier 2A) gene family: GLUT1-GLUT12, GLUT14, and 
HMIT (GLUT13) (54-56). The GLUT proteins share between 25-68% amino acid 
sequence identity with one another (54,57), and also share several signature structural and 
functional features. To date, none of the GLUT proteins have been visualized three-
dimensionally by crystallography, although GLUT1 and GLUT3 virtual structures have 
been predicted using homology modeling (58,59). 
    GLUT proteins contain 12 hydrophobic transmembrane (TM) spanning α-helical 
domains threaded together by hydrophilic loops of varying length, with a large 
intracellular loop between TM domains 6 and 7 of the protein (54,57). There is also a 
highly conserved 5 amino acid motif, RXGRR/K, which is located  in the loop between 
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TM domains 2 and 3 and duplicated in the loop between TM’s 8 and 9 (54,57). This 
sequence is found not just in the GLUTs, but in the majority of MFS superfamily proteins  
as well (60,61), and is thought to aid in determining proper membrane topology (62). In 
addition, there are certain sugar transport signatures that are commonly found in all 
GLUTs that are thought to be essential for substrate and inhibitor selectivity and 
sensitivity. Among them are a PMY domain in TM 4, a PESPRY/FLL domain in the 
large intracellular loop 6, a QQLSGIN domain in TM7 thought to aid in glucose binding, 
a GXXXXP motif in TM10 which potentially determines inhibitor and substrate binding, 
a single W in TM 11 which has been shown to be critical for transporter function in 
GLUT1, and a VPETKG in the C-terminus of the protein (Figure 1.1) (63). GLUT 
proteins also feature N- and C-termini that are intracellular, and a single glycosylation 
site on the exofacial side of the protein, either in the loop between TMs 1 and 2, or 9 and 
10 (54,57). The GLUT family can be sub-divided into three classes based on substrate 
transport and structural variations, and some of their key features are summarized in 
Table 1.1. 
    Class 1 Glucose Transporters 
    The class 1 transporters, GLUT1-4 and GLUT14, are the most well characterized of 
the group, since (with the exception of GLUT14) they were discovered relatively early 
and have been studied extensively. Loop 1-2 of class 1 GLUTs is longer than the other 
five extracellular loops, and contains a single N-linked glycosylation site; and they also 
share a QL motif in TM5, and a STSIF motif found in extracellular loop 7-8 (57). In 
addition, there is a tryptophan after the GXXXXP motif in class 1 GLUTs that is thought  
9 
 
 
Figure 1.1: Structural Homology of GLUT Proteins 
Representative schematic of the generic GLUT family structure Circles in red represent 
the structural motifs and residues present in all GLUTs:  RXGRR (loop 2 and 8), PMY 
(TM4), PESPRY/FLL (loop 6), QQLSGIN (TM7) GXXXXP (TM10), W (TM 11), and 
VPETKG (C-terminus). Circles in yellow represent residues found in class 1 and 3 
GLUTs: W (TM 10). Circles in purple represent motifs found in class 1 GLUTs only: QL 
(TM5), STSIF (loop 7). Blue arrow represents the N-linked glycosylation site for Class 3 
GLUTs at loop 9, which is longer than in Class 1 and 2 GLUT proteins. 
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to confer substrate specificity as well as sensitivity to the competitive inhibitor 
cytochalasin B (57,64-66). Class 1 GLUT’s are typically glucose transporters, though 
GLUT1, GLUT3, and GLUT4 are also able to transport dehydroascorbic acid (DHA), an 
oxidized form of vitamin C (67-69). With the exception of GLUT1, GLUT proteins 
demonstrate highly tissue-specific expression patterns. GLUT1, the first of the GLUT 
proteins to be cloned, was originally isolated from liver HepG2 cells (70), but has since 
been shown to be expressed ubiquitously throughout the body, with highest expression 
levels in erythrocytes, cardiac muscle cells, blood-tissue barrier cells, astrocytes, and in 
developing embryos (71-73). GLUT1 has often been termed a high-affinity glucose 
transporter and serves to maintain basal glucose uptake throughout the body, but is 
critical for blood-brain barrier glucose uptake (34,38,74,75). The properties of GLUT1-
mediated transport will be described in greater detail in this introduction. GLUT2 
expression is localized to pancreatic β-cells, the liver, the hepatic portal vein, intestine, 
and kidney (76). Of the class 1 GLUTs, GLUT2 has the lowest reported affinity for 
glucose and cytochalasin B; and it has been shown to transport fructose, but not 
dehydroascorbic acid (65,66). Originally, GLUT2’s low affinity for glucose was thought 
to allow it to function as a high capacity transporter, but it has been shown that high 
expression and catalytic turnover are more important factors (77).  However, in the 
context of where it is expressed, GLUT2 is thought to acts as a glucose sensor protein in 
the intestine, liver and pancreas (66). GLUT3 is a glucose transporter primarily found in 
neurons, making it the major transporter responsible for neuronal glucose uptake, but is 
also expressed in white blood cells, pre-implantation embryos, the  
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Name Class Primary 
Substrates 
CCB 
Sensitive? 
Tissue Distribution 
GLUT 1 1 Glucose, DHA Yes Ubiquitous expression in human/murine tissue, mostly 
red cells, endothelial cells, astrocytes  
GLUT 2 1 Glucose,  
Fructose 
Yes Liver, pancreas (b-cells), but also in kidney and small 
intestine absorptive cells  
GLUT 3 1 Glucose, DHA Yes Neurons, also in sperm, embryo, white blood cells, and 
carcinomas 
GLUT 4 1 Glucose, DHA Yes Fat and skeletal muscle, insulin responsive 
GLUT 5 2 Fructose No Intestine, testis, and kidney, also in skeletal muscle, fat 
cells, and brain 
GLUT 6 3 Glucose* Yes  Brain cells and spleen cells 
GLUT 7 2 Glucose,* 
Fructose,* 
No Small intestine and colon (apical membranes) 
GLUT 8 3 Glucose, 
Fructose** 
Yes Testis, brain, fat, liver, and spleen 
GLUT 9 2 Urate, Glucose, 
Fructose 
No Kidney and liver, but also in the placenta, lung, small 
intestine 
GLUT 10 3 Glucose Yes Heart, lung, brain, liver, skeletal muscle, pancreas, 
placenta and kidney" 
GLUT 11 2 Glucose, 
Fructose 
Yes  Heart (A, C) skeletal muscle (A, C), kidney (A, B), 
adipose tissue (B, C), placenta (B), pancreas (C) 
GLUT 12 3 Glucose, 
Fructose 
Yes Heart, skeletal muscle, brown adipose tissue, prostate 
GLUT 14 1 Glucose**, 
DHA**  
Yes** Testis 
HMIT  3 H
+ 
myoinositol
 
 No Brain 
 
Table 1.1: Properties of GLUT Proteins 
*  indicates substrates tested may not be primary substrate, more data needed 
** indicates unconfirmed substrate transport/affinity, no data available 
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testes, spermatozoa, and some carcinomas (64,78). Like GLUT1, GLUT3 has been 
shown to transport DHA, thus allowing neurons to potentially take up and metabolize 
vitamin C (67,68) in addition to mannose, xylose, and galactose (78). The presence of 
both GLUT3 and GLUT1 in the brain are critical for maintaining proper glucose uptake, 
and therefore energy supply in the brain. GLUT4, the insulin-sensitive glucose 
transporter, is expressed mostly in cardiac and skeletal muscle, as well as adipocytes (79). 
Unlike the other class 1 GLUT proteins, GLUT4 is targeted primarily to specialized 
intracellular pools under non-insulin stimulated conditions due to the presence of an FQQ 
motif in the N-terminus and both a dileucine motif and an endosomal targeting 
TELEYLGP in the C-terminus (80). Exposure to insulin causes massive increases in 
GLUT4 at the plasma membrane, allowing it to act as a key modulator of blood glucose 
levels in the body. GLUT4 can also transport DHA in addition to glucose (68) and works 
in concert with GLUT2 to modulate glucose homeostasis in the blood. GLUT14, the most 
recently cloned class 1 transporter, is thought to be a gene duplication of GLUT3, since it 
shares 95% sequence identity to the protein (55). Unlike GLUT3, GLUT14 is only 
expressed in the testes. Although the characterization of GLUT14 is not complete, it can 
be assumed that it is both a glucose and DHA transporter like GLUT3, with similar 
transport characteristics. 
Class 2 Glucose Transporters 
    Unlike class 1 GLUTs, the class 2 transporters (GLUT5, GLUT7, GLUT9, and 
GLUT11) are primarily fructose transporters, although they have been shown to transport 
glucose as well as other substrates, such as uric acid (81-85). Another notable difference 
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that distinguishes class 2 GLUTs is the absence of the tryptophan residue the GXXXXP 
motif in TM10 (57). This lack of tryptophan renders class 2 GLUTs insensitive to 
cytochalasin B and aids in selectivity for fructose as opposed to glucose (57).  Like their 
class 1 counterparts, tissue-specific expression is a hallmark of class 2 GLUT proteins. 
GLUT5 was the first of the class 2 GLUTs to be discovered, and is the major fructose 
transporter in the intestines, kidney, and spermatozoa, though it has also been shown to 
be expressed at the blood-brain barrier, in skeletal muscle, and in fat (82,86,87). GLUT7 
is expressed mainly in the colon and small intestine, but may also be found in the testes 
and prostate (83). It is possible that GLUT7’s role is to transport a different substrate 
besides sugars, but as of yet, such a substrate has not been found. GLUT7 is also 
hypothesized to aid in the uptake of fructose and glucose in the gut when sugar levels are 
low (87). GLUT9 is expressed primarily in liver, kidney, and developing embryo, but is 
also found to be expressed in the heart, lung, and leukocytes (81,88). GLUT9 contains a 
dileucine motif in the N-terminus, but the motif does not sequester GLUT9 to 
intracellular pools, unlike most other GLUT family members (81). Interestingly, GLUT9 
exists as two splice variants, dubbed GLUT9a and GLUT9b, that demonstrate differential 
localization in the proximal tubules of the kidney, with GLUT9a localizing to the 
basolateral membrane, and GLUT9b localizing to the apical membrane (81,89). Studies 
show that GLUT9 appears to play an important role in mediating glucose uptake in the 
very early stages of embryonic development (88). However, the main role for GLUT9 
appears to be urate transport as evidenced by genetic and functional studies (89-91). 
Kinetic analysis indicates that GLUT9-mediated urate transport is stimulated by the 
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presence of glucose and fructose on the opposite side of the membrane, suggesting that 
GLUT9 plays a role in sugar reabsorption from the urine as well as urate clearance from 
the bloodstream (92). The final member of the class 2 glucose transporters, GLUT11, 
exists as three known splice variants, two of which have different expression patterns. 
The full length form (GLUT11L) is expressed in the brain, lung, leukocytes, small 
intestine, placenta, and liver (93), while the shorter form GLUT11S is expressed almost 
exclusively in the heart and muscle (84). The third splice variant encodes a severely 
truncated version of the protein that has yet to be characterized (93). Both the long and 
short forms of GLUT11 have been shown to transport glucose and fructose; and unlike 
the other class 2 GLUTs, GLUT11 shows a low affinity for cytochalasin B (84,93). The 
true role GLUT11 plays in physiology still remains to be determined. 
Class 3 Glucose Transporters 
    The class 3 GLUTs comprise GLUT6, GLUT8, GLUT10, GLUT12, and HMIT and 
are the least characterized of the GLUT proteins to date. Structurally, this class of 
proteins has some notable differences from the other two classes. Most strikingly, class 3 
GLUT proteins contain a single glycosylation site on loop 9-10 of the protein, as opposed 
to 1oop 1-2 for classes 1 and 2. Also, all class 3 GLUTs contain signal sequence motifs in 
either the N- or C-terminus of the protein which direct the protein to intracellular 
compartments rather than directly to the plasma membrane (57). However, despite these 
differences, class 3 GLUT proteins appear to contain the conserved tryptophan after the 
GXXXXP motif in TM 10 like class 1 transporters, as well as demonstrate tissue-specific 
expression like the other GLUT proteins. GLUT6, the first family member identified but 
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the second cloned, appears to be prevalent in the brain, spleen and leukocytes; and 
preliminary analysis shows transport activity for glucose and sensitivity to cytochalasin 
B, with low affinity for both (94). GLUT6 also contains a dileucine motif in the N-
terminus which sequesters it to intracellular pools; and to date, stimulation by a number 
of factors such as insulin, phorbol esters, and osmotic shock does not significantly recruit 
it to the plasma membrane (95). It would appear the true physiological role GLUT6 plays 
has yet to be determined. GLUT8, which was the first of the class 3 transporters to be 
cloned, is predominantly expressed in the brain, testes, liver, spleen, adipose, and lung, 
and may also be expressed in muscle, heart, and kidney (96). GLUT8 is a high-affinity 
glucose transporter that is inhibitable by cytochalasin b, but is also shown to be inhibited 
by fructose and galactose, which indicates both sugars as potential substrates for the 
transporter (96,97).  Like GLUT6, GLUT8 contains a dileucine motif in the N-terminus 
of the protein that localizes it to intracellular stores. In blastocysts, GLUT8 has been 
shown to translocate to the plasma membrane in response to insulin, since GLUT4 is 
absent at this stage of development (98). Interestingly, in fully developed mammals, 
GLUT8 recruitment to the plasma membrane has not been seen, even in the presence of 
insulin and a number of known recruitment stimulants (95,99,100). While the function of 
GLUT8 still requires further study, it is thought that GLUT8 acts as an intracellular 
glucose transporter responsible for moving glucose between organelles (99). GLUT10 
expression is localized to the heart, lung, brain, placenta, liver, kidney, pancreas, and 
skeletal muscle (101). Although initial characterization shows GLUT10 to be a high-
affinity glucose transporter that is sensitive to cytochalasin B, but not fructose (102), the 
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exact role of GLUT10 in mammals is unclear. It has been hypothesized, based on recent 
studies, that GLUT10 plays a role in vascular changes occurring in Type 2 diabetes, since 
mutations in the GLUT10 gene alter angiogenesis and cause arterial tortuosity syndrome 
(103). However, the role GLUT10 plays in both vascularization and diabetes requires 
more study. GLUT12 is localized to the heart, muscle, brain, placenta, pancreas, kidney, 
and adipose tissue (104,105). It has been shown to localize to intracellular stores, and has 
similar targeting motifs to the other class 3 GLUTs, as well as GLUT4 (104,105). 
GLUT12 is responsive to insulin, and translocates to the plasma membrane upon insulin 
stimulation as well as during hyperglycemia (106,107). GLUT12 has been identified as a 
glucose, fructose, and galactose transporter that is sensitive to cytochalasin b (104), and it 
is hypothesized to compensate for insulin-sensitive glucose transport when GLUT4 is 
knocked out in mice (108). The full role GLUT12 plays in Type 2 diabetes and insulin-
regulated glucose uptake, as well as its substrate preference remain to be seen. The last 
member of the class 3 GLUTs, HMIT or GLUT13, is a H+-myoinositol symporter, a 
secondary active carrier that shows no transport capability for hexoses even though it 
retains many signatures of glucose transport in its structure. While it is able to transport 
myoinositol on its own, the presence of protons increases its rate of transport. HMIT is 
expressed in the brain, predominantly in astrocytes, but may also be expressed in 
neurons, adipose and kidney. HMIT is localized to intracellular stores, but translocates to 
the plasma membrane upon membrane depolarization and may play an important role in 
brain myoinositol metabolism, but the physiological role it plays requires further 
characterization (109).  
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     While the GLUT family of proteins is diverse, tissue specific, and varied in function, 
the primary focus of our studies revolves around the class 1 transporter GLUT1 and its 
role in modulating glucose uptake across the blood-brain barrier. In order to understand 
how GLUT1 mediates transport in blood-brain barrier endothelial cells, it is important to 
understand GLUT1 structure and the characteristics of sugar uptake it exhibits. 
GLUT1 Structural Characteristics 
    GLUT1 is a 492 amino acid protein with a calculated molecular weight of 54,117 
Daltons. The sequence NQT at amino acids 45-47 in exofacial loop 1 comprises the 
single N-linked glycosylation sequence found in GLUT1 (Figure 1.1). It has been shown 
that glycosylation of GLUT1 is heterogeneous, causing the protein to run as a smeared 
band  from 45-65 kDa when visualized by SDS-PAGE or Western blot (110); and that 
this smeared band collapses to a single band of approximately 38 kDa upon 
deglycosylation (111). In addition, unlike some of the other GLUT proteins, 
deglycosylation of GLUT1 causes a 50% decrease in sugar uptake and a 2.5-fold 
decrease in affinity for glucose, though targeting to the plasma membrane remains 
unaffected (111). These data seems to suggest that the glycan plays a role in maintaining 
GLUT1 structure, and its affinity for substrate. The sequence GRRTLHLIGLAG, which 
corresponds to amino acids 332-343 in loop 8 and TM9 of GLUT1, is a Walker B 
nucleotide-binding domain(112-114). GLUT1 has been shown to bind ATP, which plays  
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Figure 1.2: Putative Topology of GLUT1 
Representative schematic of human GLUT1 topology showing purported transmembrane 
spanning domains (TMs), loops, and intracellular N- and C-termini. Horizontal parallel 
lines represent the plasma membrane, colored boxes represent potential symmetry of the 
TMs, and blue graphic at Asn 45 represents the glycan.  
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an important role in regulation of transport (115-117). The truncation of the last 37 amino 
acids of GLUT1’s C-terminus has also been shown to ablate transport activity and lock 
GLUT1 into an inward facing conformation that cannot bind substrate. However, GLUT1 
trafficking to the plasma membrane remains unaffected, indicating that this region is 
required to maintain the structural integrity of GLUT1 upon substrate transport (118).   
GLUT1 Secondary Structure 
    Approximately 60% of GLUT1’s amino acid sequence contains hydrophobic residues, 
leading to the prediction of twelve plasma membrane spanning α-helical domains by 
hydropathy analysis upon cloning (70). Further studies using Fourier transform infrared 
spectroscopy confirm the α-helical nature of GLUT1 (119); and circular dichroism 
spectroscopy analysis indicate that GLUT1 structure is approximately 82% α-helical, 
10% β-turn, and 8%  random coil structure (120). GLUT1 α-helices were shown to be 
perpendicular to the plasma membrane, confirming the hypothesized transmembrane-
spanning structure of the protein (121). When incubated with D-glucose, the secondary 
structure of purified GLUT1 increases in a saturable manner when measured by circular 
dichroism, while cytochalasin B appears to have no effect on structure (122). This 
demonstrates the conformational change GLUT1 undergoes upon substrate binding, and 
also shows that cytochalasin B is not transported, but seems to lock the protein in a single 
conformation. 
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GLUT1 Tertiary Structure     
The amphipathic nature of the α-helices is thought to promote arrangement of a water-
accessible sugar binding site and translocation pathway, which has been confirmed by 
scanning mutagenesis, as well as accessibility to biotinylated bis-mannose, membrane-
impermeant NHS-biotin and proteolytic enzymes (123-125). In addition, the solved 
crystal structures of the MFS family members GlpT and LacY, two of the MFS 
superfamily members, have been used as a scaffold to predict GLUT1 tertiary structure  
based on homology of helical packing and secondary structure (59,126). These models 
suggest that the first and second halves of GLUT1 exist in a symmetrical antiparallel 3-
dimensional structure, with TMs 2, 4, 5 7, 8, and 10 forming a funnel-like translocation 
channel, and TMs 3, 6, 9, and 12 acting as structural stabilizers around the outer edges of 
the protein. In contrast, the large intracellular loop 6 and the N- and C-termini of GLUT1 
appear as disordered random coil structures. The symmetry of the three-dimensional 
model, combined with some of the conserved sequence symmetry in the first and second 
halves of the protein (i.e. the GRR/K motif in TM2 and 8), has led to the hypothesis that 
GLUT1, and indeed the GLUT family of transporters, arose as a result of a gene 
duplication event (127). However, it should be noted, that while the two halves of 
GLUT1 can self associate and transport sugar when expressed separately, each half of the 
protein is unable to mediate glucose uptake individually (128).  
    GLUT1 Quaternary Structure 
     The initial analysis of GLUT1 transport and structure seemed to indicate the presence 
of a higher order oligomeric structure to the protein. Initial ligand binding studies 
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indicated the presence of two binding sites per GLUT1 transporter, one facing the 
cytosol, and one facing the extracellular space (129). Since carriers cannot present both 
endofacial and exofacial binding sites at once, this suggests the formation of  GLUT1 
dimers. When GLUT1 is purified from erythrocytes, reconstitution in cholate yields two 
species of approximately 104 and 226 kDa, respectively, when resolved by SDS-PAGE 
and size exclusion chromatography (130,131), which suggests the presence of both 
GLUT1 dimer and tetramer. The addition of reductant to the purified protein yields a 
single 104 kDa species, indicating that tetramer formation, but not dimer formation, may 
be associated with disulfide formation (131). Studies using GLUT1-GLUT4 chimerae 
expressed in CHO cells and 3T3-L1 adipocytes also suggest oligomer formation, since 
immunoprecipitation of chimerae with GLUT4 C-terminal antibody were able to pull 
down native GLUT1, but not GLUT4 (132). Finally, freeze-fracture electron microscopy 
and light scattering studies of GLUT1 in different detergents indicate the presence of 
homodimeric or homotetrameric protein structure (133). 
    Until the crystal structure of GLUT1 is solved, many details of how GLUT1 is 
arranged in the plasma membrane remain elusive. Visualizing GLUT1 in three 
dimensions may ultimately lead to clearer answers as to how it functions as a glucose 
transporter, and how it is inhibited. However, there are certain structural elements that 
have been shown to play a critical role in the mediation and regulation of glucose 
transport, such as the C-terminus, ATP-binding domain, and its quaternary structure. 
While still incomplete, many of the details of GLUT1-mediated transport have been well 
22 
 
characterized in the two systems where its expression is the highest: the erythrocyte and 
the blood-brain barrier.  
GLUT1-Mediated Transport 
   GLUT1 is primarily responsible for D-glucose transport in cells; while it recognizes 
both α and β D-glucose equally (134,135), it does not bind or transport L-glucose. In 
addition to D-glucose and DHA, GLUT1 is able to transport 2-deoxyglucose and 3-O-
methylglucose, which have been key molecules for measuring its transport properties. 
The sugar analog 2-deoxy-D-glucose (2-DOG) is a semi-metabolizable substrate that can 
be transported by GLUT1 into the cell, where it is phosphorylated by hexokinase. 2-DOG 
phosphorylation traps it inside the cell, since its phosphorylated form is not transported 
by GLUT1, and it cannot be further metabolized (136). In contrast, 3-O-methyl-D-
glucose is a sugar analog that cannot be metabolized, but can be transported by GLUT1. 
Thus, it is transported into and out of cells, mimicking D-glucose under physiological 
conditions (137). The use of these sugar analogs is preferred to D-glucose in kinetic sugar 
transport kinetics because they ensure that only protein-mediated sugar uptake, and not 
glucose metabolism, is being measured.  
    In addition, GLUT1 activity is competitively inhibited by a number of molecules such 
as cytochalasin B, phloretin, forskolin, and maltose. Cytochalasin B and forskolin bind at 
the cytosolic sugar binding site with high affinity, while maltose binds GLUT1 
extracellularly with lower affinity. Phloretin is thought to bind GLUT1 both intra- and 
extracellularly with lower affinity than cytochalasin B, though the exact binding sites for 
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all of these molecules have yet to be resolved (65,138-140). The use of radiolabeled (14C 
or 3H) and cold versions of these sugar analogs and inhibitors have been critical tools for 
studying the parameters of GLUT1-mediated transport.  
    There are four traditional assays that have been employed when performing GLUT1 
sugar uptake measurements: zero-trans entry and exit, infinite-cis entry and exit, infinite-
trans entry and exit, and equilibrium exchange transport. In these assays, cis refers to the 
side of the membrane where transport is initiated, and trans refers to the opposite side of 
the membrane. Entry refers to uptake into the cell, and exit refers to efflux out of the cell, 
when sugar is pre-loaded before measuring transport. Therefore, zero-trans measures 
transport of variable concentrations of sugar into sugar-free medium; infinite-cis 
measures transport of a fixed, saturating amount of sugar into an environment of variable 
sugar levels; and infinite-trans measures transport of variable concentrations of sugar into 
an environment of a fixed, saturating sugar concentration. Equilibrium exchange is 
unique, in that the cis and trans concentrations of sugar are identical, and transport 
measures the movement of a trace amount of radiolabeled sugar across the plasma 
membrane (42,141). The combination of these assays has been used extensively to 
elucidate the kinetics of GLUT1-mediated transport in a variety of systems, with the most 
detailed analysis performed in the red blood cell.  
Kinetics of GLUT1 Transport: The Simple Carrier 
     GLUT1-mediated transport was first characterized before the protein itself had been 
discovered. Since simple diffusion of glucose was unable to account for the rate of  
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Figure 1.2: The Simple Carrier 
Schematic representation of GLUT1-mediated transport of glucose according to the 
simple carrier model. GLUT1 is represented in green residing in the plasma membrane 
(yellow), and glucose in red. In A, a single exofacial glucose binding site is exposed, and 
binding causes a conformational change that allows translocation through GLUT1 (B) 
while occluding additional glucose binding. Glucose is released into the cytosol in C, 
exposing an endofacial binding site. Intracellular glucose can either bind to be exported, 
or, in the absence of substrate (D), GLUT1 can relax to the exofacial conformation, 
regenerating the binding site and allowing another round of uptake to occur, seen in E. 
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transport across the blood-placental barrier of sheep, the simple carrier hypothesis was 
proposed to describe glucose uptake (43). The main assumptions developed from this 
study stated the following: 1. the carrier protein was selective for glucose, 2. the carrier 
presented a single binding site on one side of the membrane at a time, and alternated 
between each side regardless of whether glucose was bound, and 3. transport of glucose 
was both a saturable and equilibrative process following Michaelis-Menten kinetics 
(43,141). A schematic of simple carrier transport is represented in Figure 1.2. While this 
was able to partially describe the kinetics of GLUT1 glucose uptake, studies using 
inhibitors such as ethylidene glucose, isopropylidene glucose, and trimethyglucose, 
demonstrated an asymmetrical inhibition of transport when glucose entry and exit were 
measured (137). Similar results were also seen with cytochalasin B, phloretin, and 
maltose (139). In addition, further cytochalasin B binding studies demonstrated that 
affinity for exofacial ligand was reduced in a complex manner when cytochalasin B was 
bound internally (129,142). These studies led to the rejection of the simple carrier model 
for GLUT1 transport, instead favoring another model where GLUT1 presents two 
simultaneous sugar binding sites intra- and extracellularly. This model is known as the 
fixed site carrier. 
Kinetics of GLUT1 Transport: The Fixed Site Carrier 
    The fixed site carrier model of transport states that the carrier presents simultaneous 
entry and exit sites for substrate binding; and the availability of two substrate binding 
sites allows for simultaneous bidirectional transport. Originally, this model proposed that 
a monomer of GLUT1 presented simultaneous binding sites at both sides of the plasma 
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membrane with different affinities for glucose and inhibitors; and that sugar bound inside 
and outside the cell passed one another through the same translocation channel during 
transport. (143). While this  model partially explains the asymmetry seen in GLUT1 
transport and inhibition, it does little to explain how binding of substrate on one side of 
the membrane changes the affinity for substrate on the other side (129); or how low 
concentrations of inhibitor on one side of the membrane are able to increase the affinity 
for inhibitor on the opposite side of the membrane. In an analogous fashion, sugar or 
inhibitor on one side of the membrane can stimulate uptake of sugar on the other side of 
the membrane (called trans acceleration) (143,144). However, taking into account the 
oligomeric structure of GLUT1, a modified fixed site carrier model could explain such 
kinetic phenomena. GLUT1 is thought to exist as a tetramer, with each complex 
presenting two cytosolic sugar binding sites and two exofacial sugar binding sites. The 
monomers are thought to be arranged in an anti-parallel manner, meaning that if one 
subunit is presenting a sugar binding site, the adjacent subunits must present a sugar exit 
site. While each subunit is able to form a glucose translocation pathway and function as a 
simple carrier independently, the movement of one subunit during sugar transport 
allosterically affects the movements of the other subunits, thus allowing bidirectional 
transport to take place (Figure 1.3). Inter-subunit interaction also allows binding of 
substrate at one site to cooperatively alter the affinity for substrate at the other sites 
(144,145). While transport in most cell types expressing GLUT1 fits the modified fixed 
site model, special considerations must be made when measuring red cell transport, due 
to its complexity (146). 
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Figure 1.3: The Modified Fixed Site Carrier 
Schematic representation of GLUT1-mediated transport according to the modified fixed-
site carrier model. One half of a GLUT1 tetramer is represented in green residing in the 
plasma membrane (yellow), extracellular glucose is represented in red, and cytosolic 
glucose in blue. In A, endofacial and exofacial glucose binding sites are simultaneously 
presented at both sides of the plasma membrane. Glucose is able to bind both sites 
simultaneously, inducing a conformational change in both subunits and bidirectional 
transport, seen in B. Upon glucose release from GLUT1, binding sites are regenerated in 
the opposite configuration from A, allowing glucose transport to once again occur at 
either side of the plasma membrane, shown in C and D, with dashed lines representing a 
second round of transport. Presumably, the surrounding subunits adjacent to the two 
represented here would present binding sites in opposition to their neighbor, allowing 
transport of up to four glucose molecules, two into the cell, and two out.  Binding of 
glucose at one site is sufficient to induce conformational change in the surrounding 
subunits, regardless of whether all glucose binding sites are filled.  
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    GLUT1-mediated transport in human erythrocytes cells is unique in that it has been 
shown to be a multiphasic process. At low concentrations of 3-OMG, transport appears to 
be biphasic with fast and slow components of uptake corresponding to sugar translocation 
and release into the cytosol, respectively (147,148). Quench-flow analysis at very short 
time points reveals the presence of a third, rapid phase of transport which corresponds to 
glucose binding to GLUT1 in a temperature-sensitive manner (149). All three phases of 
transport have been shown to be protein-mediated, though the exact mechanism of how 
glucose is moving through GLUT1 at each phase remains unclear (148,149). The 
complexity seen while measuring transport in erythrocytes has led to the hypothesis that 
GLUT1 has non-catalytic sugar binding sites that interact with glucose and can form a 
cage for sugar, preventing free diffusion into the cytosol after transport (147). Similarly, 
it has been proposed that an unstirred layer exists within the cytosol of erythrocytes, 
slowing glucose diffusion upon release by GLUT1 (141). While the true mechanism of 
red cell transport has yet to be revealed, the presence of such complex kinetics must be 
considered when using erythrocyte GLUT1 transport measurements as a benchmark since 
traditional assays tend to over- or underestimate the true kinetics involved (148,149). 
Adding further to the complexity of GLUT1-mediated transport is its regulation by the 
nucleotide ATP. 
ATP and GLUT1 Transport 
   The effect of ATP on GLUT-mediated sugar uptake was first observed in studies 
measuring both glucose uptake and tryptophan fluorescence. ATP was shown to increase 
the affinity for glucose and decrease the Vmax for glucose transport in GLUT1 residing in 
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inside-out vesicles. Further studies demonstrated that ATP decreases Vmax  and decreases 
Km (increasing affinity) for sugar uptake into red cells, while decreasing Vmax and 
increasing Km (decreasing affinity) for sugar exit (150). In addition, ATP enhances the 
ability of glucose to quench intrinsic tryptophan fluorescence of GLUT1 through 
conformational change upon substrate binding both in vesicles and stripped ghosts 
(151,152). While fluorescence quenching with ADP and AMP was also observed, there 
was no change to the rate of glucose uptake or affinity for glucose in the presence of 
either nucleotide (151,152). In addition, the nucleotides GTP, UTP, and ITP also show no 
effect on GLUT1 function (153). It has since been demonstrated that ATP, ADP, and 
AMP can all directly bind to GLUT1 and competitively displace one another from the 
protein, but that GLUT1 itself has no detectable ATPase activity (113,115). ATP has also 
been shown to bind GLUT1 in a cooperative manner (154). Taken together, these data 
indicate that the rate of GLUT1-mediated uptake and its affinity for glucose are directly 
related to the amount of ATP/AMP present in the cytosol, allowing both nucleotides to 
modulate sugar uptake in direct response to cellular energy levels.   
    While the mechanism of how ATP controls GLUT1 sugar uptake is not clearly 
defined, the available data offers several clues as to how this process may occur. ATP 
binding to GLUT1 reduces reactivity of the C-terminus of the protein with specific 
antibodies raised against it (115);  and studies using sulfo-NHS-biotin to modify lysines 
in both intracellular loop 6 and the C-terminus suggest interaction between these regions 
upon ATP binding (155). Thus, ATP binding to GLUT1 induces conformational changes 
in the protein that have two consequences: 1. an increase in the affinity for extracellular 
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glucose, which slows down uptake into the cell; and 2. an interaction between the C-
terminus and loop 6, that could potentially form a “cage” structure on the cytosolic face 
of the protein. This cage structure is thought to occlude glucose diffusion into the cytosol, 
either physically or through the presence of additional glucose binding sites. Occluded 
glucose can either be transported back out of the cell, interact with additional glucose 
binding sites within the cage, or eventually be released into the cytosol (117).  
Other Suppressors of GLUT1-Mediated Transport 
    In addition to ATP, there are other molecules that are able to down regulate GLUT1-
mediated glucose uptake in cells, usually through direct interaction. The membrane 
protein stomatin, which was first identified as band 7.2 when GLUT1 was first purified 
from red blood cells, has been shown to play a possible role in suppressing glucose 
uptake. It was observed that stomatin co-immunoprecipitates with GLUT1 using GLUT1 
antibodies; however, direct interaction between stomatin and GLUT1 has not yet been 
proven, only speculated (156). Further studies show that during erythropoesis, GLUT1-
mediated sugar uptake is suppressed and DHA uptake increased in human erythroblasts 
and erythrocytes. This conversion from transport of glucose to DHA is thought to be 
modulated by stomatin through its interaction with GLUT1 (157). However, since it is 
expressed in a wide variety of cells and little is known about its function, the role 
stomatin plays in red blood cell and other mammalian cells requires further study. 
    Barbiturates, which are frequently used as anesthetics, have been shown to suppress 
the Vmax of GLUT1-mediated transport by approximately 50% in red blood cells, blood-
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brain barrier endothelial cells, and other cell types in addition to reducing cerebral blood 
flow and metabolism (158,159). Fluorescence studies have shown that barbiturates 
directly interact with GLUT1, quenching intrinsic fluorescence in a dose-dependent 
manner regardless of the presence of D-glucose. This indicates a direct interaction with 
GLUT1 that is dose-dependent and not competitive with substrate binding. Unlike ATP, 
barbiturate treatment does not alter the Km for D-glucose, and the suppression of glucose 
uptake appears to be isoform-specific, with little effect seen in GLUT4-containing cells 
(159).  
GLUT1 Transport Upregulation by Signaling Molecules 
    Control of energy homeostasis is critical for maintaining cell viability; and there are a 
number of mechanisms that control GLUT1-mediated glucose uptake based on metabolic 
demand. While red blood cells contain the highest concentration of GLUT1 of all cell 
types, they lack the regulatory machinery to control GLUT1 expression and translocation 
(129). Consequently, GLUT1 regulation has been most studied in cells where it is the 
primary glucose transporter, such as the endothelium comprising blood-tissue barriers, as 
well as in cells where GLUT1 and GLUT4 are co-expressed, such as insulin-sensitive 
tissues. While not normally insulin-sensitive, GLUT1 translocation to the plasma 
membrane is increased approximately twofold in insulin-sensitive cells along with other 
proteins in the constitutive recycling pathway, including transferrin (160). Activation of 
the phosphatidlyinositol-3-kinase (PI3K) pathway has been shown to mediate this 
increase in GLUT1 translocation (161,162) during insulin stimulation.  
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    Since growth factors are responsible for activating energetically demanding cellular 
processes, GLUT1 is an ideal target to supply much needed glucose to meet cellular 
metabolic requirements. Molecules such as platelet-derived growth factor (PGDF), 
vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and 
epidermal growth factor (EGF) play a key role in modulating GLUT1 expression and 
localization in a variety of cell types. In 3T3-L1 adipocytes, treatment with PDGF for 10 
minutes increases GLUT1 translocation to the plasma membrane and doubles 2-DOG 
uptake via PI3K activity (163). VEGF treatment of bovine retinal endothelial cells for 24 
hours increases plasma membrane GLUT1 1.7-fold, while increasing 3-OMG uptake 
approximately 1.6-fold with no change to GLUT1 mRNA expression or total GLUT1 
protein. In contrast to insulin-sensitive cells, this translocation appears to be mediated by 
protein kinase C activity (164). Chronic exposure of 3T3-L1 adipocytes to FGF-21 
increases GLUT1 expression and 2-DOG uptake, and this effect is further enhanced upon 
activation of PPARγ, an anti-diabetes target (165). Finally, mouse embryonic cells 
exposed to EGF for 12-24 hours demonstrate increased GLUT1 expression and 2-DOG 
uptake that appears to be modulated by PKC and p38/MAPK (166).  
GLUT1 and Cancer 
    GLUT1 expression has been shown to be upregulated by inflammatory oncogenic 
signaling molecules, such as the cytokines transforming growth factor beta (TGFβ) and 
tumor necrosis factor alpha (TNFα) (167). As a result, high levels of GLUT1 have been 
observed in a number of cancers (168). Overexpression of GLUT1 and increased glucose 
uptake have been observed in carcinomas of the lung, breast, colon, kidney, brain, ovary 
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and squamous cell, among others (169-175). For the most part, detection of GLUT1 in 
tumor tissue is associated with poor prognosis, tumor angiogenesis, and metastasis; and it 
is often used as a marker protein to flag patients who may need more aggressive 
treatment. Tumor cells are noted for their high metabolic demand and low oxygen 
consumption as compared to healthy cells. Their switch from relying on oxidative 
metabolism to anaerobic glycolysis for energy has been deemed the Warburg effect, and 
upregulation of GLUT1 plays a critical role in supplying tumors with much needed 
glucose (176). As a result, GLUT1’s role as the energy supplier in tumor cells has made it 
a desirable target for anti-cancer therapy in recent years.  
GLUT1 Regulation and Metabolic Stress 
    Since GLUT1 is responsible for delivering glucose to cells for energy metabolism, its 
activity is tightly bound to the cell’s metabolic state. When conditions exist that cause 
decreases in intracellular ATP, GLUT1 transport is upregulated in order to maintain 
adequate energy supplies. Chronic hypoxia has been shown to increase GLUT1 
expression through the activity of hypoxia inducible factor 1 alpha (HIF1α), which 
regulates expression of the GLUT1 gene in addition to other glycolytic targets (177,178). 
In addition, the AMP-dependent kinase (AMPK) can directly modulate GLUT1 
expression and trafficking during chronic hypoxia and hypoglycemia through HIF1α-
dependent and independent mechanisms (179-181). Similarly, when cells are subjected to 
acute hyperosmotic shock, both GLUT1 trafficking to the plasma membrane and intrinsic 
activity have been shown to increase (182). Inhibition of oxidative metabolism with 
reagents such as cyanide and carbonyl cyanide-p-trifluoromethoxyphenylhydrazone 
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(FCCP) also acutely increase GLUT1-mediated transport without increasing GLUT1 
expression, localization, or total GLUT1 protein through de-repression of plasma 
membrane GLUT1 transport activity (183,184). 
    While the sources and length of metabolic stress may vary greatly in these studies, the 
common theme is that ATP depletion increases GLUT1-mediated transport in a variety of 
cell types. In the context of brain metabolism and its dependence on blood-brain barrier 
glucose transport, it is important to consider these regulatory mechanisms for insight into 
how GLUT1 mediates glucose uptake under normal and metabolically stressed 
conditions.  
GLUT1-Mediated Transport at the Blood-Brain Barrier 
    GLUT1-mediated transport at the blood-brain barrier is, as with red cells, a saturable, 
equilibrative process that follows Michaelis-Menten kinetics (34,36). However, there are 
some notable differences between the roles of red cells and endothelial cells in regards to 
glucose transport. First, the red blood cell primarily acts as a glucose carrier, as the high 
GLUT1 content allows for rapid equilibration of glucose between serum and red cell 
cytoplasm, which increases the glucose carrying capacity of the blood.  Blood-brain 
barrier endothelial cells, on the other hand, mediate transcellular glucose uptake that is 
primarily unidirectional in nature, with uptake occurring at the luminal side of the cell, 
and efflux taking place at the abluminal surface. Second, healthy red cells are thought to 
have uniform distribution of GLUT1 throughout the plasma membrane (135), while 
blood-brain barrier endothelial cells demonstrate polarization with unequal distribution of 
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GLUT1 between the luminal and abluminal faces of the cell (26,185). In addition, 
approximately 50% of GLUT1 is sequestered in intracellular stores in endothelial cells, 
unlike red blood cells (186). Finally, as previously mentioned, red cell glucose transport 
is unique in its kinetic complexity (146); and for reasons that remain unclear, this 
complexity may be lacking in blood-brain barrier endothelial cells (187).  
GLUT1 Deficiency Syndrome: Blood-Brain Barrier Transport Dysfunction 
    Impairment of blood-brain barrier glucose transport has dire consequences on brain 
function. A rare pathological condition called GLUT1-deficiency syndrome (GLUT1-
DS) has been shown to cause a number of detrimental symptoms in young children which 
result from reduced endothelial glucose uptake. GLUT1-DS causes seizures, delayed 
development and head growth, impaired motor skills, learning disabilities, and mental 
handicap if left untreated (188,189). GLUT1-DS can result from a number of point 
mutations, truncations, deletions, or insertions in the GLUT1 gene that cause alteration of 
GLUT1 structure and ablation of glucose and DHA transport function (188,190,191). 
While homozygous mutations are lethal, heterozygous mutations are autosomal 
dominant, and result in an approximately 50% reduction in GLUT1-mediated transport 
across the blood-brain barrier (192). While there is no cure, a high fat ketogenic diet has 
been shown to alleviate the symptoms of GLUT-DS and allow for more normal brain 
metabolism and development (193). The damaging effects of impaired blood-brain 
barrier transport underscore both the critical role GLUT1 plays in supplying fuel for the 
brain, and the need for proper regulation of blood-brain barrier glucose transport. 
Understanding how the blood-brain barrier regulates GLUT1-mediated glucose uptake, 
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especially during stress conditions, is therefore critical to gaining insight into both brain 
metabolism and whole organism development and homeostasis. 
Blood-Brain Barrier Transport and Metabolic Stress 
    As in other cell types, the effects of both chronic and acute metabolic stress have been 
studied in blood-brain barrier endothelial cells. Chronic hypoxia has been shown to 
increase both brain vascularization, total GLUT1 protein, and glucose uptake in the 
blood-brain barriers of rats (194). Similarly, GLUT1 mRNA and protein expression are 
both increased in cultured endothelial cells subjected to hypoxic conditions for several 
hours (195). The blood-brain barrier of rats subjected to hypoglycemia for 5-14 days 
shows increases in GLUT1 mRNA, total protein, and glucose uptake, while chronic 
hyperglycemia has no effect on GLUT1 expression or transport activity (196,197). Brain 
injury caused by trauma increases GLUT1 expression in the vasculature around the site 
of injury; while unilateral ischemia-hypoxia, which causes developmental brain damage, 
has also been shown to upregulate GLUT1 gene expression and total protein in rat brain 
(198,199). These results indicate that, as in other cell types, GLUT1 expression, 
localization, and transport are all increased in blood-brain barrier endothelial cells 
exposed to chronic metabolic stresses.  
    Acute metabolic stress has been shown to upregulate GLUT1-mediated transport at the 
blood-brain barrier. However, the mechanisms underlying this regulation are not as well 
defined as those of the chronic stress response. Acute metabolic stress induced by 
seizures has demonstrated that the glucose transport capacity of the blood-brain barrier 
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doubles in rat brains with no apparent change to the Km for glucose (200). Interestingly, 
immunogold labeling of blood-brain barrier GLUT1 during seizures does not indicate 
increased total plasma membrane protein, but in some cases shows decreased GLUT1 
presence (200). These findings lead to several questions about how GLUT1 activity is 
modulated at the blood-brain barrier during acute metabolic stress.  
Remaining Questions 
    Analysis of blood-brain barrier endothelial cell responses to metabolic stress seems to 
indicate two distinct mechanisms of regulation. While chronic responses mirror those 
seen in other cell types, i.e. increased GLUT1 gene expression, protein levels, and 
eventual trafficking to the plasma membrane, the acute response data raise some 
questions. First, what are the effects of acute glucose deprivation on blood-brain barrier 
endothelial cells? There is little data demonstrating the effect of acute hypoglycemia at 
the blood-brain barrier. Since blood-tissue barrier endothelial cells have a higher 
mitochondrial content than those of the peripheral endothelium, they may be able to sense 
rapid changes in glucose more easily than their less energetically demanding counterparts 
(26). On a similar note, how does inhibition of oxidative phosphorylation affect 
endothelial cell glucose uptake? Since mitochondria are abundant in blood-tissue barrier 
endothelial cells, inhibition of oxidative phosphorylation would likely have a profound 
effect on energy metabolism and by extension glucose uptake, but again, there is little 
data to demonstrate this in endothelial cells.  
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    Perhaps the most glaring question is this: how is the increase in glucose uptake 
mediated during acute stress in blood-brain barrier endothelial cells? Since the increases 
in transport were seen during seizures (where brain energy demand rapidly increases), 
this seems to imply communication between the brain cells and the blood-brain barrier 
(200,201). Are neurons and astrocytes required to modulate increased blood-brain barrier 
glucose uptake, or can the endothelium sense changes in energy availability and 
compensate on its own? Are GLUT1 expression, trafficking, or intrinsic activity affected 
during acute stress, or is the effect a combination of these events? Finally, what signaling 
factors, if any, play a role in modulating glucose transport at the blood-brain barrier? 
GLUT1 is subject to regulation by a number of different pathways, including the AMPK, 
HIF1α, PKC, and PI3K signaling cascades (161,166,177,202,203). Are these pathways 
involved in the acute stress response, or are there others that may play a role? 
    The data presented in this thesis attempt to answer some of the questions above by 
defining the time course, kinetics, and mechanism of GLUT1-mediated transport during a 
variety of acute metabolic stresses in cultured blood-brain barrier endothelial cells as well 
as by examining the signaling cascades that may play a role in modulating transport 
under normal and acute stress conditions.  
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CHAPTER II 
EVALUATION OF THE BRAIN MICROVASCULAR ENDOTHELIAL CELL 
LINE bEnd.3 AS A MODEL SYSTEM FOR BLOOD-BRAIN BARRIER 
GLUCOSE TRANSPORT STUDIES 
Abstract 
    Studies of the effects of acute metabolic stress on blood-brain barrier endothelial cell 
glucose transport are difficult in vivo due to temporal resolution and substrate delivery 
required to accurately measure transport. Primary cultures of endothelial cells are 
notoriously difficult to isolate and sustain for long periods without compromising their 
integrity. Therefore cultured cell systems are ideal for their flexibility and resilience in 
the face of such studies. Here we evaluate the murine brain microvascular endothelial cell 
line bEnd.3 as a model system for studying blood-brain barrier endothelial cell transport 
during acute metabolic stress. Sequence alignment of human and mouse GLUT1 protein 
shows approximately 97% sequence homology between the proteins, with 100% 
homology in the purported ATP binding domain, 88% in the N-terminus, 100% in the C-
terminus, and 97% in loop 6 of the protein. A combination of Western blot, qPCR, and 
pharmacological analysis shows that GLUT1 is the primary transporter responsible for 
glucose uptake in these cells. Sugar uptake measurements using 2-DOG and 3-OMG 
demonstrate that GLUT1-mediated transport is detectable and inhibitable by cytochalasin 
B in bEnd.3 cells. Analysis of kinetic data shows that zero-trans entry and equilibrium 
exchange sugar uptake data for both 2-DOG and 3-OMG are mostly comparable to 
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published values seen in human red blood cells. These results taken together indicate that 
bEnd.3 cells are an adequate model system for studying the effects of acute metabolic 
stress on GLUT1-mediated glucose transport.  
Introduction 
    Understanding how nutrient transport across the blood-brain barrier is affected is 
important for studying regulation of brain metabolism. However, the mechanics of 
undertaking transport studies have proven difficult for a number of reasons. While in vivo 
systems are ideal for transport studies, they present significant obstacles for data 
collection. First, there are severe restrictions placed on human studies, limiting the types 
of assays that can be performed. Second, specific isolation and delivery of the substrate 
of interest to the blood-brain barrier is very difficult to achieve in a repeatable manner. 
Finally, the complexity of a whole organism prevents the ability to specifically knock 
down, inhibit, or stimulate a target without inducing system wide effects on the organism. 
As a result, in vitro studies are preferred when studying blood-brain barrier nutrient 
uptake since the system is more isolated, and therefore better able to be controlled than an 
in vivo model.  
    There are two main sources of in vitro systems for studying blood-brain barrier 
nutrient transport: primary cell lines and immortalized cell lines. Primary cells offer 
many advantages, such as retention of in vivo endothelial cell characteristics and the 
formation of monolayers of cells that form tight junctions in culture, which can be quite 
useful in simulating the blood-brain barrier (204). However, there are a number of 
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drawbacks to using primary cell systems, such as large amounts of time and biological 
material needed to generate a cell line, the variability of cell quality from sample to 
sample, and the limited passages that can be performed before cells senesce or die (204) 
that may make them undesirable for long term studies. Immortalized cells, on the other 
hand, offer a number of advantages over primary cells, such as rapid growth, the ability 
to passage many times, consistency of sample, and retention of many blood-brain barrier 
endothelial characteristics (205). However, in order to choose the correct system, an 
analysis must be done of that system’s characteristics to determine if it is a good choice.  
    Glucose transport at the blood-brain barrier, which is mediated by the facilitative 
transporter GLUT1, is upregulated during acute metabolic stress (200,201). However, 
there are limited studies elucidating the details of how GLUT1 is modulating the increase 
in sugar transport under these conditions. Therefore, we sought to examine how GLUT1-
mediated sugar transport is regulated during acute metabolic stress. However, in order to 
study blood-brain barrier transport, an appropriate system was necessary. The inability to 
induce acute stress in vivo without causing either irreparable harm to the organism or 
compensatory reactions to stress throughout the body made an animal system a poor 
choice. Primary cultured in vitro models, though desirable for their close resemblance of 
in vivo blood-brain barrier mechanics, were not ideal due to time and biological material 
constraints. As a result, we sought to use the immortalized in vitro tissue culture system 
bEnd.3 as a model for our studies.  
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    The murine microvascular endothelial cell line bEnd.3 is a polyoma virus middle T-
antigen transformed cell line isolated from brain microvessels. Like low passage primary 
endothelial cells, bEnd.3 cells demonstrate a spindle-shaped morphology, express tight 
junction proteins, can be induced to form tight junctions, and have been shown to express 
GLUT1 by reverse-transcriptase (RT) PCR (205). Therefore, we sought to establish the 
feasibility of the bEnd.3 cell line as a system for studying regulation of glucose transport 
during acute metabolic stress. We compared the sequences of human and mouse GLUT1 
for differences in regulatory regions of the protein. We screened whole-cell lysates for 
the presence of GLUT1, and probed for GLUT family expression using RT and 
quantitative PCR. Using the glucose analogs 2-deoxyglucose (2-DOG) and 3-O-
methylglucose (3-OMG) we examined the time courses and kinetics of GLUT1-mediated 
sugar uptake in bEnd.3 cells and compared the values to published red blood cell data. 
Our results show that GLUT1 is the primary transporter responsible for sodium-
independent glucose uptake in bEnd.3 cells. Transport is inhibitable by cytochalasin B 
(CCB) and, for the most part, comparable to established erythrocyte kinetic data. We also 
detected GLUT8 and GLUT9 mRNA in bEnd.3 cells, though expression is very low 
compared to GLUT1. No other class 1 glucose transporters were detected in these cells 
based on our analysis. Although not a primary cell line or an in vivo animal model, our 
data suggests that bEnd.3 cells are an adequate cell line that provide an opportunity to 
study sugar transport in cells derived from the endothelium. 
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Experimental Procedures 
Tissue Culture 
    bEnd.3 cells were obtained from ATCC and maintained in Dulbecco’s Modified Eagle 
Medium (DMEM) from Gibco supplemented with 10% fetal bovine serum (FBS) from 
Hyclone and 1% Penicillin/Streptomycin (Pen/Strep) solution (Gibco) at 37°C in a 
humidified 5% CO2 incubator. All experiments were performed at cell confluence. Plates 
were subcultured at a ratio of 1:2-1:3 by washing with sterile Dulbecco’s phosphate 
buffered saline (DPBS) and treating with 0.5% Trypsin-EDTA (Gibco) for 5-7 minutes at 
37°C. Passages 3-16 were used in all experiments.  
Antibodies 
   A custom, affinity-purified rabbit polyclonal antibody raised against a synthetic peptide 
corresponding to GLUT1 amino acids 480-492 was produced by New England Peptide. 
HRP conjugated Goat anti-rabbit secondary antibodies were obtained from Bio Rad and 
Jackson Labs.  
Buffers 
    Cell lysis buffer consisted of 5 mM HEPES, 5 mM MgCl2, 150 mM NaCl, 50 µM 
EDTA, and 1% SDS. Uptake stop solution included 10µM cytochalasin B (CCB, Sigma) 
and 100 µM phloretin (Sigma) in DPBS. TAE buffer consisted of 40 mM Tris base, 1 
mM EDTA, and 20 mM acetic acid. TBS was composed of 20 mM Tris base and 135 
mM NaCl, pH 7.6. TBST comprised TBS buffer with 0.2% Tween-20.  
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Sequence Alignment of Human and Mouse GLUT1 Protein 
    The amino acid sequence for human GLUT1 (GenPept number NP_006507.2) and 
mouse GLUT1 (GenPept number NP_035530.2) were obtained from NCBI. Sequences 
were aligned and compared using the ClustalW algorithm. 
Western Blotting of bEnd.3 Cells 
    Confluent 100 mm dishes of bEnd.3 cells were washed twice with DPBS, lysed, and 
analyzed for total protein concentration using a micro BCA kit (Pierce). Lysates were 
normalized for total protein and run on either 4-12% Bis-Tris or 10% Bis-Tris gels in 
MES buffer (Invitrogen), transferred to PVDF membranes (ThermoFisher), blocked with 
either 5 or 10% bovine serum albumin (BSA), and probed with a 1:5,000 dilution of C-
terminal antibody, a 1:20,000 dilution of HRP-conjugated goat anti-rabbit was also used. 
Chemiluminescence was visualized either on film, or using the Fujifilm LAS-3000 with 
SuperSignal Reagent (Pierce).  
Endpoint Reverse Transcriptase PCR 
    Confluent bEnd.3 cells were washed twice with ice cold DPBS, and total RNA was 
isolated using the RNeasy Mini Kit and Qiashredder (Qiagen). Reverse transcriptase PCR 
was carried out on bEnd.3 RNA samples using Qiagen’s One-Step RT-PCR Kit as per kit 
instructions using the following primers (IDT):  GLUT1: 5’-
GAACCTGTTGGCCTTTGTGGC-3’ and 5’-GCTGGCGGTAGGCGGGTGAGCG-3’ 
which produced a DNA fragment of 515 bp,  GLUT2: 5’-
AAGAGGAGACTGAAGGATCTGC -3’ and 5’-GTAGCAGAC ACTGCAGAAGAGC-
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3’ which produced a DNA fragment of 461 bp (206), GLUT3: 5’-
CGCCGTGACTGTTGCCACG ATC-3’ and 5’-CCACAGTTCTTCAGAGCCC AGA-3’ 
which produced a DNA fragment of 517 bp, GLUT4: 5’-
TGCAACGTGGCTGGGTAGGC AA-3’ and 5’-AGGGAGTACTGTGAGAGCCAG A-
3’ which produced a DNA fragment of 444 bp, GLUT5: 5’-
CTAACTGGAGTCCCCGCAGGCC-3’ and 5’-GACACAGACAATGCTGATATAG-3’ 
which produced a DNA fragment of 548 bp, GLUT6: 5’-
ACCCCCTGATGTTCGTGGGGCC-3’ and 5’-CGTAGAGCCCCAGTGTCAGGTT-3’ 
which produced a DNA fragment of 592 bp,  GLUT7: 5’-
CCCATGTACCTGGGAGAACTGG-3’ and 5’-ATCAGCTGCCAGCGCAGGGGCC-3’ 
which produced a DNA fragment of 390 bp, GLUT8: 5’-
TGGCTGGCCGTGCTGGGCTGTG-3’ and 5’-AGTAGGTACCAAAGGCACTCAT-3’ 
which produced a DNA fragment of 464 bp, GLUT9: 5’-
TTGAGCGCTTAGGAAGGAGACC-3’ and 5’-ACCGCTGCAGAACGAGGCAATG-3’ 
which produced a DNA fragment of 163 bp, GLUT10: 5’-
AATGCCAGCCAGCAGGTGGAT C-3’ and 5’-AGGACAGCGGTCAGCCCATAG A-
3’ which produced a DNA fragment of 526 bp, GLUT12:  5’-
GTGCTTAGTGAGATCTTTCCC-3’ and 5’-CCTTTGCTAGCTCCACTGATAT-3’ 
which produced a DNA fragment of 244 bp, and HMIT:  5’-
CTGAAATCTATCCTCTCTGGGC-3’ and 5’-CAATGTACCTCCCTTCATCCGA-3’ 
which produced a DNA fragment of 284 bp. Analysis of DNA fragments was performed 
using agarose gel electrophoresis  (1.5% agarose in TAE buffer). Bands were visualized 
46 
 
with ethidium bromide staining under UV light on a Fujifilm LAS-3000 and gels were 
analyzed using Fujifilm Multigauge 3.0 software. 
Quantitative Reverse Transcriptase PCR 
    Total RNA was isolated from bEnd.3 cells as described above, and quantitative RT-
PCR was performed using an iScript One-Step RT-PCR Kit with SYBR Green (Bio-
Rad). Each reaction was run in duplicate using the following primers (IDT): GLUT1: 5’-
AGCCCTGCTACAGTGTAT-3’ and 5’- AGGTCTCGGGTCACATC-3’ which 
generated a DNA fragment of 135 bp; GLUT8: 5’- TGTGGGCATAATCCAGGT-3’ and 
5’-GGGT CAGTTTGAAGTAGGTAC-3’ which produced a DNA fragment of 140 bp, 
GLUT9: 5’-CTCAT TGTGGGACGGTT-3’ and 5’-CAGATGAAGAT GGCAGT-3’ 
which produced a DNA fragment of 132 bp, and as a mouse expression control, EIF1α: 
5’-CAACATCGTCGTAATCGGACA-3’ and 5’-GCTTAAGACCCAGGCGTACTT-3’ 
which was used to normalize PCR data (207). Samples were run on an MJ-Research 
PTC-200 Peltier Thermal Cycler with a Chromo4 Real Time PCR detector using Opticon 
Monitor 3 software (Bio-Rad). Relative RNA expression was quantitated using the ∆∆CT 
method and results graphed using Synergy Software’s Kaleidagraph Version 4.0. All 
primers were verified using Qiagen’s One-Step RT-PCR Kit and run on a 2% agarose gel 
in TAE. Bands were visualized by ethidium bromide staining under UV light on a 
Fujifilm LAS-3000 and gels were analyzed using Fujifilm Multigauge 3.0 software. 
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Time Course of 2-DOG Uptake 
    Confluent 150 mm2 dishes of bEnd.3 cells were split into 12-well plates the afternoon 
before each experiment. On the day of the assay, cells were placed in serum-free DMEM 
for 2 hours at 37°C. Cells were washed with 1 ml of DPBS, incubated in 0.5 ml wash 
media for 10 minutes at 37°C. Wash medium was drained, and cells were treated with 
400 µl of 100 µM 2-deoxy-D-glucose (2-DOG) with 2.5 µCi [3H]-2-deoxyglucose ([3H]-
2-DOG) in DPBS in the absence or presence of 10 µm CCB or 10 µm CCB plus 50 µm 
phlorizin (Sigma) at 37°C. Uptake was measured at various time points from 0 to 15 
minutes and was stopped by adding 1 ml of uptake stop solution followed immediately by 
media aspiration. Each well was washed twice more with 1 ml of stop solution and 
treated with 0.5 ml of cell lysis buffer. Samples were counted in duplicate by liquid 
scintillation spectrometry (Beckman). Each measurement was performed in triplicate. 
Protein concentrations for each sample were determined using Pierce’s BCA protein 
assay kit.  
Time Course of 3-OMG Uptake 
    Uptake was measured as described above, with the following modifications: After the 
wash step was performed and cells were incubated for 10 minutes at 37°C, plates were 
immediately placed on ice and cooled to 4°C prior to uptake measurement. Wash medium 
was drained, and cells were treated with 400 µl of 5 mM 3-O-methylglucose (3-OMG) 
containing 2.5 µCi/ml [3H]-3-O-methylglucose ([3H]-3-OMG) in DPBS in the absence or 
presence of 10 µM CCB. Uptake proceeded for various time points from 0 to 15 minutes, 
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plus a 100 minute equilibrium point, and was stopped by adding 1 ml of uptake stop 
solution and the media immediately aspirated. Samples were processed as described 
above. 
Zero-Trans 2-DOG Dose Response Sugar Uptake Measurements 
    Confluent 150 mm2 dishes of bEnd.3 cells were prepared as described. After wash 
medium was drained, cells were treated with 400 µl of increasing concentrations of 2-
deoxy-D-glucose (2-DOG) with 2.5 µCi [3H]-2-deoxyglucose ([3H]-2-DOG) in DPBS at 
37°C. Uptake proceeded for 5 minutes, and was stopped by adding 1 ml of uptake stop 
solution and the media immediately aspirated. Each well was washed twice more with 1 
ml of stop solution and treated with 0.5 ml of cell lysis buffer. Samples were then 
processed as described previously 
Zero-Trans 3-OMG Dose Response Sugar Uptake Measurements 
    Confluent 150 mm2 dishes of bEnd.3 cells were prepared as described and cooled to 
4°C prior to uptake measurement. After wash medium was drained, cells were treated 
with 400 µl of increasing concentrations of 3-O-methylglucose (3-OMG) containing 2.5 
µCi/ml [3H]-3-O-methylglucose ([3H]-3-OMG) in DPBS. Uptake proceeded for 15 
seconds at 5 mM and 10 mM 3-OMG, and for 30 seconds at 20 and 40 mM 3-OMG. 
Uptake was stopped by adding 1 ml of uptake stop solution and the media immediately 
aspirated. Each well was washed twice more with 1 ml of stop solution and treated with 
0.5 ml of cell lysis buffer and processed as described.  
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Equilibrium Exchange Sugar Uptake Measurements 
    In these experiments, intracellular concentrations of 3-OMG are equal to extracellular 
3-OMG, therefore transport is measured using [3H]-3-OMG. Transport measurements 
were similar to zero-trans uptake measurements with the following modifications: Cells 
were serum-depleted in DMEM containing 5, 10, 20, or 40 mM 3-OMG for 2 hours. 
Cells were washed and incubated as previously described with wash media containing 5, 
10, 20, or 40 mM 3-OMG in DPBS. Uptake was measured and terminated as described 
previously. Cells were then washed and processed as above.  
Cytochalasin B and 3-OMG Inhibition of 2-DOG Uptake Measurements 
    Transport measurements were performed as above with the following modifications: 
Cells were serum-depleted in DMEM containing 25 mM glucose for two hours prior to 
measuring uptake, washed with 1.5 ml DPBS, and allowed to incubate at 37°C for 15 
minutes. Plates were maintained at 37°C throughout transport measurements. Uptake 
solutions consisted of 100 µM 2-deoxy-D-glucose (2-DOG) with 2.5 µCi [3H]-2-
deoxyglucose ([3H]-2-DOG) plus increasing concentrations of either CCB from 0.1 µM 
to 10 µM or 3-OMG from 0.1 mM to 40 mM. Uptake proceeded for 5 minutes, at which 
time uptake was stopped and the cells were washed and processed as described 
previously. 
Analysis of Sugar Uptake 
    All data analysis was performed using Synergy Software’s Kaleidagraph Version 4.0. 
For time course experiments, background counts were subtracted and uptake was 
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normalized to total protein per well. Data was fit using either linear regression (2-DOG) 
or a single exponential (3-OMG). For zero-trans and equilibrium exchange transport 
experiments, background counts were subtracted and uptake, v, was normalized to total 
protein/well. Sugar uptake data was fitted to the Michaelis-Menten equation (Equation 1):  
𝑣 = 𝑉𝑚𝑎𝑥[𝑆]
𝐾𝑚 +  [𝑆] 
by non-linear regression and Vmax and Km values were extracted from the fits. For 
cytochalasin B and 3-OMG inhibition experiments, sugar uptake data was fitted to the 
equation (Equation 2): 
𝑣 = 𝑘[𝑆] +  𝐽(1 − [𝐼]Ki(app) + [I]) 
where J is the rate of protein-mediated transport and I is the inhibitor used. From this 
equation, the inhibition constant (Kiapp) for CCB inhibition of transport was extracted 
from the fit.  
Results 
Sequence Alignment of Human and Mouse GLUT1 
    In order to compare the structural differences between human and mouse GLUT1, 
sequence alignments were performed using sequence data from NCBI. The aligned 
sequences for human and mouse GLUT1 are shown in Figure 2.1, with the key amino 
acid differences summarized in Table 2.1. Human and mouse GLUT1 share 
approximately  97%  total sequence homology with one another, and differ by 17 amino 
acids out of 492. The majority of amino acid differences occur in the N-terminal half of  
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GLUT1HUMAN      MEPSSKKLTGRLMLAVGGAVLGSLQFGYNTGVINAPQKVIEEFYNQTWVHRYGESILPTT 60 
GLUT1MOUSE      MDPSSKKVTGRLMLAVGGAVLGSLQFGYNTGVINAPQKVIEEFYNQTWNHRIGEPIPSTT 60 
                *:*****:**************************************** ** **.* .** 
 
GLUT1HUMAN      LTTLWSLSVAIFSVGGMIGSFSVGLFVNRFGRRNSMLMMNLLAFVSAVLMGFSKLGKSFE 120 
GLUT1MOUSE      LTTLWSLSVAIFSVGGMIGSFSVGLFVNRFGRRNSMLMMNLLAFVAAVLMGFSKLGKSFE 120 
                *********************************************:************** 
 
GLUT1HUMAN      MLILGRFIIGVYCGLTTGFVPMYVGEVSPTALRGALGTLHQLGIVVGILIAQVFGLDSIM 180 
GLUT1MOUSE      MLILGRFIIGVYCGLTTGFVPMYVGEVSPTALRGALGTLHQLGIVVGILIAQVFGLDSIM 180 
                ************************************************************ 
 
GLUT1HUMAN      GNKDLWPLLLSIIFIPALLQCIVLPFCPESPRFLLINRNEENRAKSVLKKLRGTADVTHD 240 
GLUT1MOUSE      GNADLWPLLLSVVFVPALLQCILLPFCPESPRFLLINRNEENRAKSVLKKLRGTADVTRD 240 
                ** ********::*:*******:***********************************:* 
 
GLUT1HUMAN      LQEMKEESRQMMREKKVTILELFRSPAYRQPILIAVVLQLSQQLSGINAVFYYSTSIFEK 300 
GLUT1MOUSE      LQEMKEEGRQMMREKKVTILELFRSPAYRQPILIAVVLQLSQQLSGINAVFYYSTSIFEK 300 
                *******.**************************************************** 
 
GLUT1HUMAN      AGVQQPVYATIGSGIVNTAFTVVSLFVVERAGRRTLHLIGLAGMAGCAILMTIALALLEQ 360 
GLUT1MOUSE      AGVQQPVYATIGSGIVNTAFTVVSLFVVERAGRRTLHLIGLAGMAGCAVLMTIALALLER 360 
                ************************************************:**********: 
 
GLUT1HUMAN      LPWMSYLSIVAIFGFVAFFEVGPGPIPWFIVAELFSQGPRPAAIAVAGFSNWTSNFIVGM 420 
GLUT1MOUSE      LPWMSYLSIVAIFGFVAFFEVGPGPIPWFIVAELFSQGPRPARIAVAGFSNWTSNFIVGM 420 
                ****************************************** ***************** 
 
GLUT1HUMAN      CFQYVEQLCGPYVFIIFTVLLVLFFIFTYFKVPETKGRTFDEIASGFRQGGASQSDKTPE 480 
GLUT1MOUSE      CFQYVEQLCGPYVFIIFTVLLVLFFIFTYFKVPETKGRTFDEIASGFRQGGASQSDKTPE 480 
                ************************************************************ 
 
GLUT1HUMAN      ELFHPLGADSQV 492 
GLUT1MOUSE      ELFHPLGADSQV 492 
                ************ 
Figure 2.1: Sequence Alignment of Human and Mouse GLUT1 
ClustalW alignment of human and mouse sequences of GLUT1. The colors of each 
amino acid are representative of the following: nonpolar amino acid (red), polar 
uncharged amino acid (green), acidic amino acid (blue), basic amino acid (purple). 
Asterisks represent conserved amino acids, colons represent conserved charge or 
sidechain size, single dots represent conserved charge, but different sidechain size, and 
gaps represent nonconserved amino acids. 
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Amino Acid 
Number 
Human Sequence Mouse 
Sequence 
Location 
2 E D N-terminus 
8 L V N-terminus 
49** V N Loop 1 
52** Y I Loop 1 
55* S P Loop 1 
57** L P Loop 1 
58* P S Loop 1 
106 S A TM 3 
183** K A Loop 5 
192 I V TM 6 
193 I V TM 6 
195 I V TM 6 
203 V L TM 6 
239 H R Loop 6 
248* S G Loop 6 
349 L V TM 9 
360 Q R Loop 9 
403** A R TM 11 
Table 2.1 Sequence Difference Between Human and Mouse GLUT1 
The colors indicate the following side chain properties: Red, nonpolar; Green, polar 
uncharged; Blue, acidic; Purple, basic 
* indicates moderate amino acid substitution 
** indicates significant amino acid substitution 
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the protein, most notably in loop 1 surrounding the glycosylation site at N45. Comparison 
of the first 16 amino acids of the N-terminus, the last 30 amino acids of the C-terminus, 
loop 6, and ATP binding region of GLUT1 comprising loop 8/TM 9 show sequence of 
88%, 100%, 97%, and 100% respectively. While most sequence differences are 
conservative in structure and charge, there are five sites that show significant variation 
between human and mouse GLUT1: V49N, Y52I, L57P, K183A and A403R. The impact 
that these differences in sequence have on substrate specificity are unknown at this time. 
Overall, these results indicate that mouse GLUT1 should be detectable by human GLUT1 
C-terminal antibodies. Also, mouse GLUT1 should also undergo regulation by ATP in a 
similar manner to human GLUT1.  
Western Blot of bEnd.3 Cells 
    In order to evaluate the bEnd.3 cell line as a potential system for studying GLUT1 
sugar uptake, we sought to detect the presence of GLUT1 protein by Western blot. 
Antibodies raised against both the C-terminus and loop 6 of human GLUT1 were used to 
probe whole cell lysates of bEnd.3 cells, and the results can be seen in Figure 
2.2.Western blot data indicates that GLUT1 appears as a single band of approximately 55 
kDa when probed with C-terminal antibody. The loop 6 antibody demonstrates a faint 
GLUT1 band at approximately 55 kDa with higher order bands at approximately 60, 62, 
and 97 kDa respectively. Results are consistent with the initial characterization of bEnd.3 
cells by RT-PCR, which demonstrate expression of GLUT1 mRNA. 
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Figure 2.2: Western blot of bEnd.3 Cells 
Whole cell lysates of bEnd.3 cells were prepared and analyzed for total protein. 20 µg of 
lysate was loaded onto a gel and probed with C-terminal (CT) GLUT1 antibody. A 
schematic underneath the blot represent GLUT1, with the red circle indicating the region 
of the protein against which the antibody was raised.  
 
 
 
 
55 
 
 
 
 
 
Figure 2.3: RT-PCR Screen for GLUT Family Members 
A. Total cellular RNA was isolated from bEnd.3 cells, normalized, and used as a template 
for RT-PCR. Samples were analyzed on a 1.5% agarose gel in duplicate and visualized 
with ethidium bromide. Other class 2 and class 3 GLUT family members, which showed 
no expression, are not shown. B. Relative Expression of GLUT1, GLUT8, and GLUT9 in 
bEnd.3 Cells Ordinate, relative expression (%). Abscissa: relative SYBR green 
fluorescence Cells were processed as in A and 100 ng of total RNA was used for each 
reaction. Primers specific to GLUT1, GLUT8, and GLUT9 were used in each reaction, 
and results are plotted relative to GLUT expression.  
A 
B 
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Transporter Name  Class  mRNA Detected  
GLUT 1  1  Yes  
GLUT 2  1  No  
GLUT 3  1  No  
GLUT 4  1  No  
GLUT 5  2  No  
GLUT 6  3  No  
GLUT 7  2  No  
GLUT 8  3  Yes  
GLUT 9  2  Yes  
GLUT 10  3  No  
GLUT 11  2  N/A*  
GLUT 12  3  No  
HMIT (GLUT 13)  3  No  
GLUT 14  1  N/A*  
 
Table 2.2: Summary of GLUTs Expressed in bEnd.3 Cells 
* indicates that expression of this GLUT is not known to occur in mice 
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Endpoint RT-PCR and qPCR of bEnd.3 Cells 
    Since the majority of glucose transport in mice is known to be facilitated by 12 of the 
14 GLUT proteins, we next sought to identify which family members were present in 
bEnd.3 cells. The presence of other GLUTs, particularly class 1 family members which 
are primarily glucose transporters, would impact the feasibility of kinetic studies of 
bEnd.3 GLUT1. Therefore, using primers specific to each GLUT, we isolated total RNA 
from bEnd.3 cells, normalized template and primer concentrations, and performed RT-
PCR in order to detect the presence of GLUT family member expression. Representative 
results are seen in Figure 2.3A and summarized in Table 2.2. While no class 1 transporter 
message was detected other than GLUT1, GLUT8, a class 3 transporter, and GLUT9, a 
class 2 transporter, were shown to be expressed. 
   Having detected the presence of GLUT8 and GLUT9, we next sought to determine the 
relative expression of each transporter. Since RT-PCR is not quantitative, we used 
quantitative RT-PCR to examine expression of GLUT proteins in bEnd.3 cells using total 
mRNA as a template. Analysis of the results indicates that while GLUT8 and GLUT9 
mRNA are detected, GLUT1 expression is approximately 33-fold higher than either 
GLUT8 or GLUT9 mRNA. This indicates that GLUT1 is the major GLUT family 
member responsible for glucose uptake in bEnd.3 cells.  
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Figure 2.4: Time Course of 2-DOG Uptake 
A. Time course of 100 µM 2-DOG uptake in control cells (♦), cells incubated with 10 µM 
CCB (●) or 10 µM CCB + 50 µM phlorizin (■). Ordinate, 2-DOG uptake (dpm per µg 
total cell protein); Abscissa, time in seconds. Data points represent the mean ± S.E. of 
three separate determinations. B. Time course of 5 mM 3-OMG uptake in control cells 
(♦) or cells incubated with 10 µM CCB (●). Ordinate, 3-OMG uptake (dpm per µg total 
cell protein); Abscissa, time in seconds (note log scale). Data points represent the mean ± 
S.E. of three separate determinations. 
 
A 
B 
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Time Courses of 2-DOG and 3-OMG Uptake 
    We next sought to determine the properties of GLUT1-mediated uptake in bEnd.3 cells 
including whether they are able to transport the sugar analogs 2-DOG and 3-OMG. 2-
DOG is transported by GLUT1 and phosphorylated by hexokinase, trapping it inside the 
cell. 3-OMG is a transportable, non-metabolizable substrate of GLUT1. If sugar uptake is 
protein mediated and GLUT1 specific, then CCB should inhibit uptake regardless of the 
time transport is measured. In addition, we wanted to determine whether active transport 
played a role in bEnd.3 sugar uptake. The sodium-glucose co-transporters of the SGLT 
family are responsible for active uptake of glucose against its concentration gradient, and 
are sensitive to the compound phlorizin (46).  Therefore, we measured sugar uptake using 
100 µM 2-DOG at 37° C over time points ranging from 0-15 minutes in the absence or 
presence of 10 µM CCB and 50 µM phlorizin (Figure 2.4A) Results indicate that 2-DOG 
uptake progresses in a linear fashion over time, and that uptake is inhibited completely by 
CCB. The addition of phorizin had no effect on the background uptake of 2-DOG in the 
presence of CCB.  This result is consistent with sodium independent glucose uptake 
mediated by GLUT1. 
    We next sought to determine whether bEnd.3 cells could transport 3-OMG. Therefore, 
we measured sugar uptake of 5 mM 3-OMG at 4° C over time points ranging from 0-15 
minutes, plus a 100 minute equilibrium point in the absence or presence of 10 µM CCB 
(Figure 2.4B). Results show that 3-OMG reached equilibration within 3-4 minutes, and as 
with 2-DOG uptake, was CCB inhibitable, again reinforcing that uptake is protein  
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Figure 2.5: bEnd.3 Zero-Trans 2-DOG and 3-OMG Uptake 
A. Concentration dependence of zero-trans 2-DOG uptake. Ordinate, rate of 
unidirectional 2-DOG uptake in mol/µg total protein/min; Abscissa, [2-DOG] in 
millimolar. Each point represents the mean ± S.E. of five experiments. B. Concentration 
dependence of zero-trans 3-OMG uptake. Ordinate, rate of unidirectional 3-OMG uptake 
in mol/µg total protein/min; Abscissa, [3-OMG] in millimolar. Each point represents the 
mean ± S.E. of three experiments. Curves were generated from fits to equation 1. 
 
 
A 
B 
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mediated and GLUT1 specific. Time courses of 3-OMG uptake were also performed in 
the absence and presence of sodium using either potassium or cholate based buffers to 
confirm the lack of sodium dependent glucose uptake (data not shown). Results indicate 
no difference in sugar uptake in the absence or presence of sodium, confirming the results 
seen with phlorizin.  
2-DOG and 3-OMG Zero-Trans Uptake Measurements 
    In order to determine the kinetics of bEnd.3 GLUT1-mediated uptake, we examined 
the concentration dependence of 2-DOG uptake under zero-trans conditions using a 5 
minute time point obtained from the time course in Figure 2.4A. Uptake was measured at  
concentrations from 0.1 to 20 mM 2-DOG at 37° C and results are shown in Figure 2.5A. 
After fitting to equation 1, a Vmax of 2.9 ± 0.5 x10-11 mol/µg/min was obtained, with a Km 
of 7 ± 3 mM, indicating that 2-DOG uptake obeys Michaelis-Menten kinetics. Results 
were converted to mol/cell/min and compared to red cell values in Table 2.3 
    Due to the rapid equilibration of 3-OMG seen in Figure 2.4B, concentration 
dependence of 3-OMG uptake was measured at 4° C for 15 seconds at 5 and 10 mM 3-
OMG, and 30 seconds at 20 and 40 mM 3-OMG (Figure 2.4B). When the data was fit to 
equation 1, a Vmax of 36 ± 0.6 mol/L/min and a Km of 6.7 ± 0.4 mM were obtained. The 
data for 2-DOG and 3-OMG transport were converted into the appropriate units and 
compared to published values for human red blood cell transport, as seen in Table 2.3. In 
order to verify the Km for 3-OMG, we performed a dose response to 3-OMG using 2-
DOG as the transportable sugar. Since 2-DOG and 3-OMG compete for the same binding  
62 
 
 2-DOG Vmax 
(mol/cell/min) 
2-DOG 
Km 
(mM) 
3-OMG Vmax 
(mol/L/min) 
3-OMG 
Km (mM) 
3-OMG Vmax 
(mol/L/min) 
EE** 
3-OMG 
Km 
(mM) 
EE** 
Red 
Cell* 4.6x10
-14 ± 0.6x10-14 8± 3 1 ± 0.2 0.4 ± 0.1 9 ± 3 23± 6 
bEnd.3 
Cell 3.4 ± 1.3x10
-14 7 ± 3 36 ± 0.6 6.7 ± 0.4 114 ± 53 19 ± 19 
 
Table 2.3: Summary of 2-DOG and 3-OMG Kinetics in bEnd.3 and Red Cells 
* as referenced in (208) 
** denotes equilibrium exchange transport 
 
 
Figure 2.6: 2-DOG Dose Response to 3-OMG 
Concentration dependence of zero-trans 2-DOG uptake was measured in the presence of 
increasing concentration of 3-OMG. Ordinate, total 2-DOG uptake/µg total protein; 
Abscissa, [3-OMG] in millimolar. Each point represents the mean ± S.E. of two 
experiments. Curve was generated by fitting data to equation 2, and Km was determined 
from the fit. 
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site, one can be used to inhibit the other. The Km can be extracted for the inhibiting sugar 
(3-OMG) when fit to equation 2. Therefore, using a fixed concentration of 2-DOG (100 
µM), we measured inhibition of uptake by 3-OMG over a range of concentrations from 0-
40 mM (Figure 2.6). Results were fit to equation 2, and a Kiapp of 14 mM was obtained 
for 3-OMG. Results are summarized in Table 2.3. Based on these experiments, 2-DOG 
zero-trans uptake is in agreement with red cell values, while 3-OMG zero-trans uptake 
appears to have a 35-fold higher Vmax and 30-fold higher Km than established values for 
GLUT1-mediated sugar transport in red blood cells at ice temperature.  
Equilibrium Exchange 3-OMG Uptake 
   Since endothelial cells are rarely depleted of intracellular sugar in vivo, we next 
measured sugar uptake in bEnd.3 cells under equilibrium exchange conditions that more 
closely resemble those experienced at the blood-brain barrier. Increasing concentrations 
of 3-OMG were added to bEnd.3 cells prior to uptake so intracellular and extracellular 
glucose could equilibrate. Cells were then cooled to 4° C, and unidirectional uptake was 
measured using a trace amount of [3H]-3-OMG in increasing concentrations of cold 3-
OMG from 5-20 mM (Figure 2.7). Results were fit to equation 1, yielding a Vmax of 114 
± 53 mol/L/min with a Km of 6.7 ± 0.4 mM. Results were compared to known red cell 
values in Table 2.3. Based on these experiments, equilibrium exchange transport in 
bEnd.3 cells is approximately 12-fold faster than red cell Vmax, while Km values are in 
agreement with those previously published. Equilibrium exchange transport is also 3-fold  
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Figure 2.7: bEnd.3 Equilibrium Exchange Transport 
Cells were pre-loaded 5-20 mM of 3-OMG and allowed to equilibrate before cooling to 4 
°C and measuring unidirectional 3-OMG uptake Ordinate rate of 3-OMG uptake in mol/ 
µg total protein/minute. Abscissa 3-OMG concentration in mM. Curves were computed 
using equation 1. Each point represents the mean ± S.E. for three experiments. 
 
 
Figure 2.8: Dose Response to CCB 
Concentration dependence of zero-trans 2-DOG uptake was measured in the presence of 
increasing concentration of CCB. Ordinate, 2-DOG uptake/µg total protein; Abscissa, 
[CCB] in nM. Each point represents the mean ± S.E. of three experiments. Curve was 
generated by fitting data to equation 2, and Ki was determined from the fit. 
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faster than zero-trans uptake in bEnd.3 cells, indicating that trans-acceleration is 
occurring. 
bEnd.3 Dose Response to CCB 
    CCB is a specific competitive inhibitor of GLUT-mediated transport with a known Ki 
of 100-200 nM (138). Based on the differences seen between bEnd.3 Vmax and Km values 
from red cells, we wanted to measure the Ki for CCB inhibition of bEnd.3 glucose 
transport to see if there were differences between murine and human cells. We used 100 
µM 2-DOG to measure sugar uptake with increasing concentrations of CCB and fit the 
data to equation 2 (Figure 2.8). Based on our analysis, the Ki obtained was 122 ± 47 nM 
and agrees with red cell values for the Ki of CCB. 
Discussion 
    In this study, we characterized the bEnd.3 cell line as a potential system for studying 
acute metabolic stress at the blood-brain barrier. We compared sequences for human and 
mouse GLUT1, and screened bEnd.3 cells for not only GLUT1 expression, but also other 
GLUT family members by RT and qPCR. We detected GLUT1 protein in bEnd.3 cells by 
Western blot, and characterized the kinetics of 2-DOG and 3-OMG uptake, as well as 
CCB inhibition of transport. Finally, we compared the values obtained from transport 
studies to established values in red blood cells. Detecting GLUT1 mRNA and protein in 
bEnd.3 cells with anti-human GLUT1 antibodies was unsurprising based on sequence 
alignment and preliminary characterization of the cell line (205). The absence of other 
class 1 GLUTs 2, 3, and 4 is beneficial, since each of these proteins is able to transport 2-
66 
 
DOG and 3-OMG, and each is CCB sensitive. In addition, the varying Vmax and Km 
values for 2-DOG and 3-OMG uptake by these proteins would complicate the kinetic 
analysis of bEnd.3 sugar uptake. The presence of GLUT8 and GLUT9 mRNA was an 
unexpected result, since GLUT8 is traditionally thought to be localized to neurons and 
astrocytes (97), and GLUT9 is primarily found in digestive tissues (81). However, our 
data suggest that relative expression of these proteins in comparison to GLUT1 is too low 
to contribute significantly to sugar uptake in bEnd.3 cells. In addition, GLUT8 is not 
shown to be expressed at the plasma membrane, so its contribution to glucose uptake 
would not be a factor, even if protein resides in bEnd.3 cells (100). GLUT9 is CCB 
insensitive, so its contribution to sugar uptake could be readily accounted for in the 
presence of CCB and subtracted out of total uptake seen in bEnd.3 cells. However, our 
observations demonstrate that the majority of sugar transport is CCB inhibitable and 
sodium insensitive in bEnd.3 cells. In addition, GLUT9 demonstrates slow glucose 
uptake in the absence of urate, since urate and glucose have been shown to stimulate the 
uptake of one another when on the opposite sides of the cell membrane (92). As a result, 
even if GLUT9 protein exists in bEnd.3 cells, it is unlikely that it can contribute 
significantly to the kinetics of sugar uptake in bEnd.3 cells. 
    Because of the differences in sequence between human and mouse GLUT1, we wanted 
to compare the transport data we obtained to kinetics measured in a well established 
GLUT1-containing system using two known substrates of human GLUT1: 2-DOG and 3-
OMG. The red blood cell is the best characterized cell system for studying GLUT1-
mediated transport, and for this reason we chose them as a standard. Our results show 
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that bEnd.3 cells are able to transport 2-DOG in a saturable manner with Vmax and Km 
values that are almost identical to red blood cells, indicating that the sequence differences 
between human and mouse GLUT1 don’t seem to affect 2-DOG binding. This data is 
also in agreement with tentative 2-DOG uptake experiments performed in bEnd.3 cells 
(205). Although the Km of hexokinase for 2-DOG is approximately the same as the 
concentration of 2-DOG used to measure uptake (100 µM), our analysis seems to indicate 
that hexokinase activity is not affecting 2-DOG uptake by GLUT1. Since uptake 
proceeds in a linear fashion during the time course experiment, the free 2-DOG is very 
low compared to 2-DOG phosphorylated by hexokinase, therefore free 2-DOG is unlikely 
to play a role in affecting the kinetics of GLUT1-mediated uptake. When 3-OMG is used 
as an inhibitor of 2-DOG uptake (Figure 2.6), the measurements become more complex. 
3-OMG rapidly equilibrates at 37 °C even at low concentrations, which complicates 
measurements of 2-DOG uptake in the following ways: 1. 2-DOG and 3-OMG compete 
for entry into the cell via GLUT1, thus inhibiting 2-DOG uptake; 2. 3-OMG on the inside 
of the cell will stimulate uptake of 2-DOG outside the cell by trans-acceleration; and 3. 
3-OMG inside the cell will inhibit 2-DOG exit from the cell, however, 3-OMG will not 
affect hexokinase activity, therefore 2-DOG is still phosphorylated upon entry into the 
cell. It could be argued, therefore, that the measurements obtained in Figure 2.6 actually 
show the Vmax for hexokinase activity and the Km for GLUT1 transport of 2-DOG. 
Though imperfect, the analysis proves useful for estimating the Ki for 3-OMG in bEnd.3 
cells. 
68 
 
    There are stark differences between 3-OMG zero-trans and equilibrium exchange 
uptake in red blood cells and bEnd.3 cells. Our results show that GLUT1-mediated zero-
trans sugar uptake is 33-fold faster, while equilibrium exchange transport is 12-fold 
faster than red blood cells. In addition, bEnd.3 cells demonstrate a 30-fold lower affinity 
for 3-OMG than red blood cells in our zero-trans measurements. One possible 
explanation could be the sequence differences that confer altered GLUT1 affinity for 3-
OMG in bEnd.3 cells. However, both our 3-OMG equilibrium exchange and CCB dose 
response data argue against this, since 3-OMG equilibrium Vmax and Km and CCB Ki 
values are comparable to red blood cells. In addition, both the Vmax and Km for 3-OMG 
have been confirmed by studies from our lab in the murine fibroblast cell line 3T3-L1, in 
the 2-DOG dose response experiment, and when comparing known values in blood-brain 
barrier cells ((209) and unpublished observations). It has long been suspected that due to 
the complexity of red blood cell sugar transport and its inability to conform to current 
kinetic models, that measurements of transport, particularly 3-OMG, are underestimated 
(148,208). Based on our analysis, it would appear that this is the likely explanation for 
discrepancies between our data and current red-cell data. It is more likely that the red cell 
zero-trans 3-OMG uptake experiments need to be revisited.  
    Despite the differences in raw kinetic values for 3-OMG uptake, GLUT1-mediated 
transport in bEnd.3 cells share a signature property with red cells, namely the ability to 
undergo trans-acceleration. Our data shows that bEnd.3 3-OMG uptake is approximately 
3-fold faster in cells pre-loaded with 3-OMG versus cells containing no intracellular 
sugar. Red blood cell equilibrium exchange transport is 9-fold faster than zero-trans 
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uptake. This data indicates that sequence differences between human and murine GLUT1 
do not seem to be involved in conferring the ability to trans-accelerate in the presence of 
intracellular sugar. This data also suggests that murine GLUT1 must exist as at least a 
dimer, if not a tetramer in the plasma membrane. Since trans-acceleration is unable to 
occur with monomeric GLUT1 based on available kinetic models, it is more likely that 
bEnd.3 cells contain oligomeric GLUT1 like their red blood cell counterparts. The 
differences in the amount of trans-acceleration seen in bEnd.3 versus red cells could 
again be attributed to the complexity of red cell transport, and revisiting these 
measurements might provide clearer insight into red cell kinetics. 
     In summary, our results indicate that, despite some discrepancies between erythrocyte 
and bEnd.3 3-OMG uptake, the bEnd.3 cell line appears to be a good model system 
amenable to studying blood-brain barrier sugar uptake. Further studies will focus on the 
response of bEnd.3 cell GLUT1-mediated sugar uptake to acute metabolic stress by 
looking at both the kinetics of sugar transport and the localization of GLUT1 at the 
plasma membrane. 
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CHAPTER III 
ACUTE MODULATION OF SUGAR TRANSPORT IN BRAIN CAPILLARY 
ENDOTHELIAL CELL CULTURES DURING ACTIVATION OF THE 
METABOLIC STRESS PATHWAY 
Abstract     
    GLUT1-catalyzed equilibrative sugar transport across the mammalian blood-brain 
barrier is stimulated during acute and chronic metabolic stress; however, the mechanism 
of acute transport regulation is unknown. We have examined acute sugar transport 
regulation in the murine brain microvasculature endothelial cell line bEnd.3. Acute 
cellular metabolic stress was induced by glucose-depletion, by potassium cyanide (KCN) 
or by carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), which reduce or 
deplete intracellular ATP within 15 minutes. This results in a 1.7 to 7-fold increase in 
Vmax for zero-trans 3-O-methylglucose uptake (sugar uptake into sugar-free cells) and a 3-
10 fold increase in Vmax for equilibrium exchange transport (intracellular [sugar] = 
extracellular [sugar]). Neither GLUT1 mRNA nor total protein levels are affected by 
acute metabolic stress. Cell-surface biotinylation reveals that plasma membrane GLUT1 
levels are increased 2-3 fold by metabolic depletion while cell surface Na+,K+ATPase 
levels remain unaffected by ATP-depletion. Treatment with the AMP-activated kinase 
agonist, AICAR, increases Vmax for net 3MG uptake by 2-fold.  Glucose depletion and 
treatment with KCN, FCCP, and AICAR also increase AMP-dependent kinase 
phosphorylation in bEnd.3 cells. These results suggest that metabolic stress rapidly 
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stimulates blood-brain barrier endothelial cell sugar transport by acute up-regulation of 
plasma membrane GLUT1 levels, possibly involving AMPK activity. 
Introduction 
 The cells of the mammalian brain do not contain large stores of glycogen.  It is 
essential, therefore, that glucose uptake by the brain exceeds glucose utilization in order 
to maintain proper brain function. To enter the brain, serum glucose must cross the blood-
brain barrier: an epithelium comprising endothelial cells connected by tight junctions that 
prevent paracellular diffusion of glucose and other nutrients. Thus, glucose transport into 
the brain requires trans-endothelial cell transport. This process is catalyzed by the glucose 
transport protein GLUT1, which is expressed at both luminal and abluminal membranes 
of the endothelium (39,73,210-212). 
 Endothelial cells of the blood-brain barrier (bEND)  differ from those of the peripheral 
circulatory system (pEND) in several important ways: 1) bEND cells contain 2 to 5-fold 
more mitochondria than pEND cells (25); 2) Brain capillary walls (comprising bEND 
cells) are 40% thinner than capillary walls of the peripheral circulation  (24); 3) pEND 
cells present significantly fewer tight junctions than bEND cells (26); 4) bEND cell tight 
junction complexes result in polarized cell surface protein expression that is less marked 
or absent in pEND cells (26). The resulting bEND cell architecture may give rise to 
behaviors that differ from those of pEND cells but which resemble those of other 
metabolically active cells and thereby optimally support blood-brain barrier physiology 
(e.g. transport sensitivity to loss of cellular oxidative metabolic capacity). 
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   Although a simple, equilibrative process, GLUT1-mediated trans-endothelial cell sugar 
transport appears to be tightly regulated. Sugar transport into the brain only narrowly 
exceeds brain glucose utilization under normal conditions (13). Under conditions of 
metabolic stress, such as hypoxia (194), hypoglycemia (196,197,213), and seizures 
(75,200), the glucose import capacity of the brain is up-regulated. Endothelial cell 
affinity for transported sugars appears to be unchanged (200). There are three possible 
explanations for increased Vmax for transport: 1) Increased GLUT1 at the plasma 
membrane, either through increased protein expression or recruitment of intracellular 
stores; 2) Enhanced intrinsic activity of GLUT1 which catalyzes faster translocation of 
substrate through the carrier, as seen in the ATP-modulation of GLUT1 in erythrocytes 
(114,151,153,155,214), or 3) A combination of both effects. 
    Chronic stress induces transcriptional up-regulation of endothelial GLUT1 levels in 
vitro (215), and in vivo (216). While increased protein expression could account for acute 
stimulation of sugar transport, immunogold staining of cells during seizures has not 
conclusively demonstrated altered cellular GLUT1 content (217). 
    Between 30-50% of total cellular GLUT1 resides in cytosolic vesicles in endothelial 
cells (186). GLUT1 recruitment to the plasma membrane occurs in response to acute 
metabolic stress in rat liver epithelial cells in vitro (182) and in response to growth factor 
stimulation in bovine retinal endothelial cells (164). We therefore set out to examine 
whether cultured, brain microvessel endothelial cells respond to acute metabolic stress 
with increased sugar transport capacity and, if so, to test the hypothesis that increased 
Vmax for sugar uptake results from recruitment of intracellular GLUT1 to the plasma 
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membrane. Using the mouse brain microvascular endothelial cell line bEnd.3 (205), we 
have determined the steady-state kinetics of GLUT1-mediated sugar transport in the 
absence and presence of glucose or the metabolic poisons potassium cyanide (KCN) and 
carbonyl-cyanide-p-trifluoromethoxyphenylhydrazone (FCCP). We established 
conditions for bEnd.3 cell ATP-depletion, measured total GLUT1 mRNA and protein 
levels, and measured changes in plasma membrane levels of GLUT1. We show that ATP 
depletion of bEnd.3 cells increases Vmax for sugar transport and increases plasma 
membrane GLUT1 levels without changing endothelial cell GLUT1 mRNA or total 
GLUT1 protein levels. We also show that glucose depletion and treatment with KCN and 
FCCP increase the phosphorylation of the AMP-activated protein kinase AMPK. 
Treatment of bEnd.3 cells with the AMPK agonist AICAR increases both the Vmax for 
sugar transport and the phosphorylation of AMPK. Taken together, this data suggests a 
potential role for AMPK in regulating the acute endothelial cell response to metabolic 
stress. 
Experimental Procedures 
Tissue Culture 
    bEnd.3 cells were obtained from ATCC and maintained in Dulbecco’s Modified Eagle 
Medium (DMEM) from Gibco supplemented with 10% fetal bovine serum (FBS) from 
Hyclone and 1% Penicillin/Streptomycin (Pen/Strep) solution (Gibco) at 37°C in a 
humidified 5% CO2 incubator. All experiments were performed at cell confluence. Plates 
were subcultured at a ratio of 1:2-1:3 by washing with sterile Dulbecco’s phosphate 
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buffered saline (DPBS) and treating with 0.5% Trypsin-EDTA (Gibco) for 5-7 minutes at 
37°C. Passages 3-16 were used in all experiments.  
Antibodies 
    A custom, affinity-purified rabbit polyclonal antibody raised against a synthetic 
peptide corresponding to GLUT1 amino acids 480-492 was produced by New England 
Peptide. A mouse monoclonal antibody against Na+, K+ ATPase was purchased from 
Abcam. Rabbit polyclonal and monoclonal antibodies against AMPK and phosphorylated 
AMPK were obtained from Cell Signaling Technology. HRP conjugated Goat anti-rabbit 
and Goat anti-mouse secondary antibodies were obtained from Jackson Labs.  
Buffers 
    Cell lysis buffer consisted of 5 mM HEPES, 5 mM MgCl2, 150 mM NaCl, 50 µM 
EDTA, and 1% SDS. Uptake stop solution included 10µM cytochalasin B (CCB, Sigma) 
and 100 µM phloretin (Sigma) in DPBS. TAE Buffer consisted of 40 mM Tris base, 1 
mM EDTA, and 20 mM acetic acid. TBS was composed of 20 mM Tris base and 135 
mM NaCl, pH 7.6. TBST comprised TBS buffer with 0.2% Tween-20. Biotin Quench 
solution was composed of 250 mM Tris base. Biotin lysis buffer contained TBS with 
0.5% Triton-X-100.  
Quantitative Reverse Transcriptase PCR 
     Confluent 100 mm dishes of bEnd.3 cells were washed with DPBS, then incubated in 
DPBS, DPBS+ 5 mM KCN or DPBS+ 8 µg/ml FCCP for 10 minutes. Plates were then 
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washed 2 times in ice cold DPBS, and total RNA was isolated using Qiagen’s RNeasy kit 
and Qiashredder as per kit instructions. Quantitative RT-PCR was performed using an 
iScript One-Step RT-PCR Kit with SYBR Green (Bio-Rad). Each reaction was run in 
duplicate using the following primers (IDT): GLUT1: 5’-AGCCCTGCTACAGTGTAT-
3’ and 5’- AGGTCTCGGGTCACATC-3’ which generated a DNA fragment of 135 bp; 
GLUT8: 5’- TGTGGGCATAATCCAGGT-3’ and 5’-GGGT 
CAGTTTGAAGTAGGTAC-3’ which produced a DNA fragment of 140 bp, GLUT9: 5’-
CTCAT TGTGGGACGGTT-3’ and 5’-CAGATGAAGAT GGCAGT-3’ which produced 
a DNA fragment of 132 bp, and as a mouse expression control, EIF1α: 5’-
CAACATCGTCGTAATCGGACA-3’ and 5’-GCTTAAGACCCAGGCGTACTT-3’ 
which was used to normalize PCR data (207). Samples were run on an MJ-Research 
PTC-200 Peltier Thermal Cycler with a Chromo4 Real Time PCR detector using Opticon 
Monitor 3 software (Bio-Rad). Relative RNA expression was quantitated using the ∆∆CT 
method. All primers were verified using Qiagen’s One-Step RT-PCR Kit and run on a 
2% agarose gel in TAE. Bands were visualized by ethidium bromide staining under UV 
light on a Fujifilm LAS-3000 and gels were analyzed using Fujifilm Multigauge 3.0. 
bEnd.3 Cell ATP Depletion 
    Confluent bEnd.3 cells in 12-well dishes were washed twice with DPBS and incubated 
with DPBS + 5 mM glucose, DPBS + glucose + 5 mM  KCN, or DPBS + glucose + 8 
µg/ml FCCP for various intervals. Cells were processed and assayed using a luciferin-
luciferase based ATP assay kit per kit instructions. Luminescence measurements were 
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made using a Turner Veritas microplate luminometer or a Turner 20/20n Single Tube 
Luminometer. 
 ATP Recovery of bEnd.3 Cells 
    Confluent bEnd.3 cells in 12-well dishes were washed twice with DPBS and treated 
with DPBS + 5 mM glucose, DPBS + glucose + 5 mM KCN, or DPBS + glucose + 8 
µg/ml FCCP for 10 minutes at 37°. The media were aspirated and replaced with normal 
cell growth media (DMEM + FBS + Pen-Strep). Cells were placed at 37° in normal 
growth media and incubated for various times. Cell processing and ATP measurements 
were performed as per kit instructions.  
Zero-Trans Sugar Uptake Measurements 
    Confluent 150 mm2 dishes of bEnd.3 cells were split into 12-well plates the afternoon 
before each experiment. On the day of the assay, cells were placed in serum-free DMEM 
for 2 hours at 37°C. Plates for AMPK activation measurements were treated with 2 mM 
of AICAR (Fisher) in serum-free DMEM for 2 hours at 37°C. Cells were washed with 1 
ml of either DPBS, or DPBS containing 5 mM KCN or 8 µg/ml FCCP and containing or 
lacking 5 mM glucose. Cells were incubated in 0.5 ml wash media for 10 minutes at 
37°C, then placed on ice to cool in glucose-free medium. Incubation on ice for 10-15 
minutes depletes intracellular sugar levels (via export) without changing cytoplasmic 
ATP levels. Wash medium was drained, and cells were treated with 400 µl of increasing 
concentrations of 3-O-methylglucose (3-OMG) containing 2.5 µCi/ml [3H]-3-O-
methylglucose ([3H]-3-OMG) in DPBS in the absence and present of the appropriate 
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poison (KCN, FCCP, or AICAR). Uptake proceeded for 15 seconds at 5 mM and 10 mM 
3-OMG, and for 30 seconds at 20 and 40 mM 3-OMG. Uptake was stopped by adding 1 
ml of uptake stop solution and the media immediately aspirated. Each well was washed 
twice more with 1 ml of stop solution and treated with 0.5 ml of cell lysis buffer. Samples 
were counted in duplicate by liquid scintillation spectrometry (Beckman). Each 
measurement was performed in triplicate. Protein concentrations for each sample were 
determined using Pierce’s BCA protein assay kit.  
Equilibrium Exchange Sugar Uptake Measurements 
    In these experiments, intracellular concentrations of 3-OMG are equal to extracellular 
3-OMG, therefore transport is measured using [3H]-3-OMG. Transport measurements 
were similar to zero-trans uptake measurements with the following modifications: Cells 
were serum-depleted in DMEM containing 5, 10, 20, or 40 mM 3-OMG for 2 hours. 
Cells were washed and incubated as previously described with wash media containing 5, 
10, 20, or 40 mM 3-OMG in DPBS, DPBS with 5 mM KCN, or DPBS with 8 µg/ml 
FCCP. Uptake was measured and terminated as described previously. Cells were then 
washed and processed as above.   
Analysis of Sugar Uptake 
    All data analysis was performed using Synergy Software’s Kaleidagraph Version 4.0. 
For zero-trans and equilibrium exchange transport experiments, background counts were 
subtracted and uptake, v, was normalized to total protein/well. Sugar uptake data was 
fitted to the Michaelis-Menten equation (Equation 1): 
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𝑣 = 𝑉𝑚𝑎𝑥[𝑆]
𝐾𝑚 +  [𝑆] 
by non-linear regression and Vmax and Km values were extracted from the fits.  
Western Blotting of bEnd.3 Cells 
    Confluent 100 mm dishes of bEnd.3 cells were washed with DPBS and incubated in 
the absence or presence of 5 mM KCN or 8 µg/ml FCCP for 10 minutes; incubated in the 
absence of 5mM glucose for 30 minutes; or incubated in the presence of 2 mM AICAR 
for 2 hours as previously outlined. Cells were then washed twice with DPBS, lysed, and 
analyzed for total protein concentration using a micro BCA kit (Pierce). Lysates were 
normalized for total protein and run on either 4-12% Bis-Tris or 10% Bis-Tris gels in 
MES buffer (Invitrogen), transferred to PVDF membranes (ThermoFisher), blocked with 
either 5 or 10% bovine serum albumin (BSA), and probed with either 1:10,000 dilution of 
C-terminal antibody, a 1:5,000 dilution of mouse Na+ K+ ATPase antibody, or a 1:1,000 
dilution of rabbit AMPK or AMPK (pThr 172) antibody. A 1:30,000 dilution of either 
HRP-conjugated goat anti-rabbit or goat anti-mouse secondary antibody was also used 
(Jackson Labs). Chemiluminescence was visualized either on film, or using the Fujifilm 
LAS-3000 with SuperSignal Reagent (Pierce). Band densities were quantitated using 
ImageJ software. 
Biotinylation of bEnd.3 cells 
    150 mm2 plates of confluent bEnd.3 cells were washed twice with 25 ml of DPBS and 
incubated with 25 ml of either DPBS alone or DPBS containing 5 mM KCN or 8 µg/ml 
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FCCP for 10 minutes at 37°C. Plates were washed twice with ice-cold DPBS, and 
incubated on ice in 12 ml of DPBS containing 1 mM EZ-Link Sulfo-NHS-SS-Biotin for 
30 minutes with gentle rocking. The reaction was quenched with 2 ml biotin quench 
solution. Cells were gently scraped into solution, washed with TBS, and pelleted. After 
washing a second time with TBS, cells were resuspended in biotin lysis buffer and 
biotinylated proteins were incubated with streptavidin beads in the absence or presence of 
10,000 units (20 µL) of PNGase F (New England Biolabs) at 37°C for 1 hour. 
Biotinylated proteins were then washed and released from streptavidin beads using 150 
mM DTT. Protein concentrations were determined using BSA as a standard. Samples 
were normalized for total protein and analyzed by Western blot. 
Results 
ATP Depletion of bEnd.3 Cells 
    ATP levels were measured in bEnd.3 cells treated with PBS containing 5 mM glucose 
in the absence and presence of either 5 mM KCN or 8 µg/ml FCCP for up to two hours 
(Figure 3.1). While ATP depletion occurs within the first 15 minutes of treatment with 
both poisons, ATP levels in KCN treated cells show a small bounce by 30 minutes and 
then remain stable. ATP levels in FCCP treated cells are rapidly depleted and remain low 
throughout the time course. The effects of poisons are dose-dependent with half-maximal 
effects observed at 3 µM KCN and 0.25 ng/mL FCCP (Figure 3.2A and 3.2B). 
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Figure 3.1: ATP Depletion in bEnd.3 Cells 
Time course of ATP depletion of bEnd.3 cells incubated with PBS containing 5mM 
glucose (●), 5mM glucose +5 mM KCN (■), or 5 mM glucose + 8 µg/ml FCCP (▲). 
Ordinate, ATP levels in ng per 100 µl of cell extract. Abscissa, time of cellular exposure 
to poison in minutes. Data points represent the mean ± S.E. for three ATP assays. 
 
 
Figure 3.2: bEnd.3 Dose Dependent ATP Depletion 
Cells were exposed to varying [poison] for 10 min at 37 °C and then cooled, and cellular 
ATP content was measured as described previously. Ordinates, relative to cytoplasmic 
[ATP] (luminescence per unit of cell protein); Abscissa: A. [KCN], B. [FCCP]. Results 
are shown as mean ± S.E. for three experiments. Curves were computed assuming that 
[ATP] decreases in a saturable manner with [poison]. 
A B 
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 Figure 3.3: ATP Depletion and Recovery in bEnd.3 Cells  
A, Time course of ATP recovery following poisoning. Cells were treated with PBS 
containing 5mM glucose (●), 5mM glucose +5 mM KCN (■), or 5 mM glucose + 8 
µg/ml FCCP (▲) for 10 min and then restored to normal growth media (PBS plus 5mM 
glucose) for the times indicated. Ordinate, ATP levels in nanograms per 100 µl of 
extract. Abscissa, time (minutes) that cells were allowed to recover from initial 
poisoning. Data points represent the mean ± S.E. for three separate ATP assays. B, Time 
course of glucose depletion-induced ATP-depletion in bEnd.3 cells. Cells were treated 
with PBS containing 5 mM glucose (■) or 0 glucose (▲) for 0–230 min at 37 °C. 
Ordinate, ATP levels in ng. Abscissa, time (minutes) that cells were exposed 
to 0 or5mM glucose. Data points represent the mean ± S.E. for three separate 
ATP assays. 
A 
B 
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    We next examined the time course of ATP recovery following treatment with KCN 
and FCCP (Figure 3.3A). bEnd.3 cells were poisoned for 10 minutes, then the media 
were replaced with normal cell growth media and cells were sampled for ATP assays for 
up to two hours post-poisoning. KCN washout allows cells to recover normal ATP levels 
within 60 minutes. ATP levels in FCCP-treated cells do not recover. Removal of 
extracellular glucose rapidly decreases cytoplasmic [ATP] by 50% (Figure 3.3B). 
Zero-Trans Sugar Uptake 
    We next asked whether bEnd.3 cell ATP depletion affects sugar uptake. 3-OMG is a 
nonmetabolizable transport substrate. Sugar uptake at 10 mM 3-OMG and 4 ºC shows 
simple monoexponential kinetics with a half-time of approximately 4 min. ATP-depletion 
with FCCP (10 min at 8 µg/ml) or KCN (10 min at 5 mM) reduces the half-time for 
uptake to 2 and 1 minute respectively (Figure 3.4A) and have the following constants: 
control, equilibrium space = 5.65 ± 0.38 dpm/µg; k= 0.0032 ± 0.0005/s; FCCP, 
equilibrium space = 5.60 ±  0.53 dpm/µg, k = 0.0073 ±  0.0017/s; and KCN, equilibrium 
space = 6.43 ± 0.58 dpm/µg, k = 0.0089 ± 0.0019/s. These data indicate that the 
equilibrium 3-OMG space of the cells is not significantly affected by metabolic depletion 
indicating that poisons do not alter cell volume. The rate of sugar uptake in control and 
poisoned cells is inhibited by 84 ± 16% by the sugar transport inhibitor CCB with Ki = 
122 ± 47 nM (n = 3) indicating that sugar import is protein-mediated.  
 Vmax and Km for 3-OMG transport were obtained by nonlinear regression analysis of 
the concentration dependence of sugar uptake assuming that uptake is described by the  
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Figure 3.4: Sugar uptake at 4 °C in bEnd.3 cells.  
A, Time course of 20 mM 3-OMG uptake in control cells (●) or in cells exposed to 5mM 
KCN (■) or to 8 µg/ml FCCP (▲) for 15 min at 37 °C prior to cooling, glucose 
depletion, and transport initiation. Ordinate, 3-OMG uptake (dpm/µg total cell protein); 
Abscissa, time in seconds (note the log2 scale). Data points represent the mean ± S.E. of 
three separate experiments. Curves drawn through the points were computed by nonlinear 
regression assuming monoexponential 3-OMG uptake. B, concentration dependence of 
zero-trans 3-OMG uptake in control cells (●), cells exposed to 5mM KCN (■), 8 µg/ml 
FCCP (▲), 0 glucose (♦), or to 2mM AICAR (●) for 15 min at 37 °C. Ordinate, relative 
rate of unidirectional 3-OMG uptake; Abscissa, [3-OMG] in mM. Curves were computed 
by nonlinear regression using equation 1, and the resulting Vmax and Km(app) values are 
summarized in Table 1. Each point represents the mean ± S.E. of three to eight separate 
experiments.  
A 
B 
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. azero-trans uptake 
 
bEquilibrium exchange uptake 
 
 cKm 
c95% 
confidence 
intervals 
crelative 
Vmax 
c95% 
confidence 
intervals 
dn Km 
c95% 
confidence 
intervals 
crelative 
Vmax 
c95% 
confidence 
intervals 
dn 
Control 6.7 ± 0.4 5.1 to 8.4 1 0.9 to 1.1 12 
14.9 ± 
12.6 -62.2 to 99.9 
e3.17 ± 
0.46 -3.1 to 9.5 3 
KCN 18.7 ± 6.7 
-10.5 to 
47.9 
e,f7.32 ± 
1.2 2.1 to 12.6 6 
18.4 ± 
13.9 -41.4 to 78.3 
e10.0 ± 
3.5 -4.8 to 24.9 3 
FCCP 30.1 ± 18.4 
-48.9 to 
109.2 4.26 ± 1.4 
-1.8 to 
10.2 6 
35.9 ± 
27.8 -83.9 to 155.8 
e14.6 ± 
6.5 
-13.5 to 
42.6 3 
-Glc 29.4 ± 11.0 
-17.8 to 
76.4 
e1.7 ± 0.3 0.2 to 3.2 3   N/D 
 
 
 
 
AICAR 3.9 ± 1.9 
-20.1 to 
27.8 
e1.5 ± 0.2 -1.1 to 4.1 3   N/D   
 
Table 3.1: Summary of bEnd. 3-OMG Transport 
aunidirectional sugar uptake into cells depleted of sugar at 4ºC for 15 min 
bunidirectional sugar uptake into cells where [3MG]I = [3MG]o 
cthe concentration dependence of sugar uptake was analyzed by non-linear regression assuming Michaelis-
Menten kinetics to obtain Km and Vmax. All Vmax values are expressed relative to Vmax for zero-trans uptake 
in matched control cells. Control zero-trans 3MG uptake Vmax = 180 pmol/µg/min. Results are shown as 
mean ± SEM and the 95% confidence intervals for the analysis are indicated. 
dnumber of separate experiments in which 3MG transport was measured at least 4 different [3MG] 
eVmax is significantly greater than control Vmax for zero-trans uptake (p < 0.05) 
fKCN stimulation of 3MG Vmax for zero-trans uptake is 3.18 ± 0.92 fold greater than FCCP stimulation of 
uptake. 
N/D: values not determined 
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Michaelis-Menten equation. Control bEnd.3 cell zero-trans 3-OMG uptake is 
characterized by a Vmax of 180 ± 10 pmol/µg total cell protein/min and Km(app) of 6.7 ± 
0.4 mM (Figure 3.4B; Table 3.1). KCN and FCCP increase Vmax for 3-OMG uptake by 
(7.2 ± 1.2) and (4.3 ± 1.4) fold respectively. Km for zero-trans 3-OMG uptake increases in 
metabolically stressed cells. Transport stimulation by KCN is rapidly reversed upon 
washout of KCN at 37ºC (Figure 3.5). 
Equilibrium Exchange 3-OMG Uptake 
    Under physiological conditions, endothelial cells are bathed in serum and interstitial 
glucose, and therefore rarely experience situations where intracellular glucose is zero. We 
therefore sought to measure sugar uptake in bEnd.3 cells under equilibrium exchange 
conditions which more closely resemble those experienced in vivo.  In equilibrium 
exchange, the concentrations of intracellular and extracellular 3-OMG are identical and 
unidirectional sugar transport is measured using [3H]-3-OMG.  Equilibrium exchange 3-
OMG uptake was measured in the absence and presence of either 5 mM KCN or 8 µg/ml 
FCCP. Equilibrium 3-OMG uptake in control cells is characterized by a Vmax of 571 ± 83 
pmol/µg total cell protein/min and Km(app) of 14.9 ± 12.6 mM (Figure 3.6; Table 1). This 
suggests that as with transport in erythrocytes, unidirectional sugar uptake displays trans-
acceleration (214). KCN and FCCP increase Vmax for exchange 3-OMG uptake by (3.2 ± 
1.1)- and (4.6 ± 2.1)-fold respectively. Poisoning has no significant affect on Km for 
exchange 3-OMG uptake. 
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Figure 3.5: Time Course of Recovery from KCN Poisoning 
Cells were treated with 5 mM KCN for 15 min at 37 °C then replaced with KCN-free 
medium containing glucose for the times shown on the abscissa. The cells were cooled to 
4 °C and zero-trans 3-OMG uptake was measured at 20 mM 3-OMG. Curve was 
calculated by nonlinear regression assuming a monoexponential decay in transport rates. 
Each point represents the mean ± S.E. of three separate experiments. 
 
 
 
Figure 3.6: bEnd.3 Equilibrium Exchange Transport 
Cells were pre-loaded with increasing amounts of 3-OMG (from 5 to 40 mM) and 
allowed to equilibrate before treating for 10 min with control medium (●), 5mM KCN 
(■), or 8 µg/ml FCCP (▲) each containing the preloading [3-OMG] at 37 °C. The cells 
were cooled, and unidirectional 3-OMG uptake was  measured at 4 °C. Ordinate, relative 
rate of unidirectional 3-OMG uptake; Abscissa, [3-OMG] in mM. Curves were computed 
using Equation 1, and the resulting Vmax and Km(app) values are summarized in Table 1. 
Each point represents the mean ± S.E. for three separate experiments 
A 
B 
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 KCN and FCCP depletion of cellular [ATP] (Figure 3.2A and B) and stimulation of 3-
OMG uptake (Figure 3.7A and B) are dose dependent with K0.5 for transport stimulation 
of 0.04 ± 0.03 mM KCN and < 1 ng/mL FCCP. Zero-trans and exchange 3-OMG 
transport are equally sensitive to FCCP (Figure 3.7B).  
Quantitation of GLUT 1 mRNA using RT-PCR 
    In order to examine whether increases in zero-trans and equilibrium exchange sugar 
transport capacity are caused by up-regulation of GLUT1 expression (or any other 
GLUT), we first measured bEnd.3 GLUT1 mRNA levels using endpoint reverse 
transcriptase PCR (RT-PCR) in the absence and presence of either 5 mM KCN or 8 
µg/ml FCCP. While endpoint RT-PCR is not quantitative, the primer sets and total 
mRNA template concentrations used for each sample were the same. Our results obtained 
indicate that there are no changes in total GLUT1, mRNA levels in the presence of either 
KCN or FCCP (Figure 3.8A and B), 
   We previously detected GLUT8 and GLUT9 mRNA in bEnd.3 cells. In order to obtain 
a more quantitative analysis of expression, we used quantitative RT-PCR (qPCR) to 
probe for changes in GLUT1, GLUT8, and GLUT9 mRNA levels in the presence of 5 
mM KCN or 8 µg/ml FCCP. Four separate mRNA samples were prepared in the absence 
or presence of either 5 mM KCN or 8 µg/ml FCCP, and each template was used to run 
the qPCR. The results were analyzed using the ∆∆Ct method, averaged and compared for 
relative mRNA expression. As with the endpoint RT-PCR, our results show no  
88 
 
 
 
Figure 3.7: Concentration Dependence of Transport Stimulation by Poison 
Cells were exposed to varying [KCN] A, or [FCCP] B, for 10 min at 37 °C and then 
cooled, and 10 mM 3-OMG uptake was measured as previously described. 
Ordinates, 3-OMG uptake in dpm/µg protein; Abscissas, [poison]. 
Results are shown as mean ± S.E of at least three determinations. The curve in A was 
computed by nonlinear regression assuming that sugar uptake increases in a saturable 
manner with [poison]. K0.5 for transport stimulation by KCN is 0.04 ± 0.03mM. 
FCCP stimulation of zero-trans (■) and equilibrium exchange (■) transport are shown. 
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Figure 3.8: RT-PCR of bEnd.3 Cells  
A, end point reverse transcriptase-PCR of bEnd.3 cells using a GLUT1 primer. Cells were 
incubated for 10 min in either PBS, PBS + 5mM KCN, or PBS + 8 µg/ml FCCP before 
isolating total RNA, and reverse transcriptase-PCR was carried out using a GLUT1 
primer. Samples were run on a 1.5% agarose gel. B, Quantitation of GLUT1 band 
densities from end point RT-PCR. Ordinate, relative expression (%). Experimental 
conditions (control PBS (■), PBS + KCN (■), and PBS + FCCP(■)) are shown below the 
abscissa. C, Quantitative RT-PCR of bEnd.3 cells. Ordinate Relative expression, GLUT 
protein screened is indicated below the abscissa Cells were processed as in A and 100 ng 
of total RNA was used for each reaction, which was run twice with four replicates for 
each condition. Results are shown as mean ± S.E. Primers specific to GLUT1, GLUT8, 
and GLUT9 were used in each reaction.  
 
A B 
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significant change in GLUT1, GLUT8, or GLUT9 mRNA levels during KCN- or FCCP-
induced ATP depletion (Figure 3.8C).  
Plasma Membrane Biotinylation of bEnd.3 GLUT1 
    ATP depletion of bEnd.3 cells does not alter GLUT1 message levels. However, 
increased translation of pre-synthesized GLUT1 mRNA could increase levels of plasma 
membrane resident protein, resulting in increased zero-trans and exchange sugar transport 
capacity. To test for this possibility, cells were incubated for 10 minutes in the absence or 
presence of 5 mM KCN or 8 µg/ml FCCP, lysed, and analyzed by Western blot. (Figure 
3.9A). Two GLUT1 C-terminal antibody reactive bands are observed: a 48 kDa species 
and a more abundant and broadly mobile species of 55 kDa. Treatment of membranes 
with PNGase F causes both species to collapse to a 42 kDa GLUT1 C-terminal antibody 
reactive species (Figure 3.9C). Densitometric analysis indicates that neither the 48 kDa 
nor the 55 kDa species is significantly increased by KCN or FCCP (Figure 3.9B). This 
result combined with the qPCR results indicates that increases in zero-trans and exchange 
Vmax are not explained by either increased GLUT1 message or protein in bEnd.3 cells. 
    We next asked whether cell surface recruitment of intracellular GLUT1 was 
responsible for increased sugar transport. Cells were incubated for 10 minutes in PBS in 
the absence or presence of 5 mM KCN or 8 µg/ml FCCP, washed, and then cooled to 
4°C. Cells were then treated with a membrane-impermeable, amine-reactive biotin 
(Sulfo-NHS-SS-Biotin), the reaction was quenched and the cells lysed in detergent-
containing lysis buffer. Biotinylated proteins were precipitated with streptavidin beads,  
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Figure 3.9: Western Blot of bEnd3 Cells During Poisoning 
A, representative Western blot of whole cell lysates of bEnd.3 cells in the absence or 
presence of either 5mM KCN or 8 µg/ml of FCCP for 10 min. Total protein (20 
µg) was loaded into each lane and probed with GLUT1 C-terminal antibody. B, 
quantitation of Western blot band density. Ordinate, relative expression (%); Abscissa, 
experimental condition: PBS, PBS + KCN, and PBS + FCCP.C. Effect of PNGase F on 
GLUT1 C-terminal antibody-reactive protein mobility. Whole cell lysates (WCL) and 
cell surface biotinylated proteins (see Fig 3.10 for details) were treated with (+) or 
without (-) PNGase F (10,000 units for 1 hour at 37 ºC). Peptides were resolved by SDS-
PAGE and subjected to immunoblot analysis using GLUT1 C-terminal antibody. The 
mobility of molecular weight standards is indicated to the left of the autoradiograph. Two 
biotinylation experiments (Biotin 1 and Biotin 2) and 1 mock biotinylation (Mock) were 
carried out on bEnd.3 cells. PNGase F enriches a 42 kDa species at the expense of 55 and 
48 kDa species. 
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analyzed by Western blot (Figure 3.10A and C) and band densities were quantitated 
(Figure 3.10B and D). The blots indicate that ATP depletion of bEnd.3 cells increases 
cell surface GLUT1 C-terminal antibody reactive species by at least two-fold whereas 
surface Na+,K+ATPase levels are unaffected by metabolic stress. Interestingly, cell 
surface expression of the 48 kDa GLUT1 C-terminal antibody reactive species is 
unchanged by metabolic depletion whereas expression of the 55 kDa species is increased 
by 3 to 5 fold (Figure 3.10A and B). These results mirror the 2-7 fold increase in 3-OMG 
transport capacity produced by metabolic poisons.  
 AMP-activated protein kinase (AMPK) is a key regulator of cellular glucose transport 
and glycolysis in muscle and heart (179,202). AICAR (an AMPK agonist) enters cells via 
nucleoside transporters, is transformed to ZMP and then allosterically activates AMPK 
(218). AICAR (2 mM) treatment of bEND.3 cells for 2 hours increases Vmax for zero-
trans 3-OMG uptake (Figure 3.4B; Table 3.1) Glucose-depletion, KCN, FCCP or AICAR 
treatment of bEnd.3 cells increases AMPK phosphorylation as judged by immunoblot 
analyses using AMPK and phospho- AMPK-directed antibodies (Figure 3.11). 
Discussion 
    This study examines the hypothesis that brain microvasculature endothelial cells 
respond acutely to cellular metabolic stress with increased sugar transport capacity 
resulting from recruitment of intracellular GLUT1 stores to the plasma membrane. 
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Figure 3.10: Surface Biotinylation of bEnd.3 GLUT1 
A and C.  Representative Western blots of cell surface biotinylated bEnd.3 cell proteins 
obtained in the absence and presence of either 5 mM KCN or 8 µg/ml FCCP. Cells were 
poisoned at 37 ºC for 10 minutes before cooling to 4 ºC and biotinylation. 30 µg of total 
streptavidin-pull down protein was loaded onto each gel and blotted with either GLUT1 
C-Ab (A) or antibody raised against Na+K+ATPase (C). Band densities were quantitated 
and shown in B (GLUT1) and D (Na+K+ATPase). Ordinate, relative expression (%); 
Abscissa, experimental condition: PBS, PBS + KCN, and PBS + FCCP. In D, results are 
shown for total C-terminal antibody-reactive species (open bars), for 55 kDa C-terminal 
antibody-reactive species (gray bars) and for 48 kDa C-terminal antibody-reactive species 
(black bars). Each experiment was repeated at least three times and the results of 
quantitations (B and D) are shown as mean ± SEM. 
A B 
C D 
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Figure 3.11: AMPK Phosphorylation During Metabolic Stress 
Immunoblot analysis of bEnd.3 cell AMPK and phosphorylated AMPK content. A and B 
Whole cell lysates (20 µg protein) were resolved by SDS PAGE and immunoblotted 
using AMPK (A) and phosphorylated AMPK (B) directed antibodies. Prior to lysis, cells 
were treated for 15 min at 37 ºC with 5 M glucose (control), 0 glucose, 5 mM KCN, 8 
µg/mL FCCP or 2 mM AICAR. The mobilities of 76 and 52 kDa molecular weight 
standards are indicated. C. Quantitation of band densities. Ordinate: ratio of 
immunoreactive phosphorylated AMPK to AMPK in extracts. Abscissa: Experimental 
conditions (control PBS, 0 glucose, PBS + KCN, PBS + FCCP and PBS + AICAR). 
Results are shown as mean ± S.E.M of 3 separate experiments. 
C 
B 
A 
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Previous studies have used the metabolic poisons KCN and FCCP to induce acute 
metabolic stress in cardiomyocytes, skeletal muscle and nucleated erythrocytes. 
Metabolic depletion rapidly stimulates sugar transport in these tissues (183,219,220). In 
the present study, we demonstrate rapid depletion of ATP in bEnd.3 cells using metabolic 
poisons. ATP levels recover within 60 minutes of removal of KCN; however, the effect 
of FCCP treatment is irreversible. We also show that KCN or FCCP treatment induces a 
3.2 to 7.2 fold increase in Vmax for zero-trans and equilibrium exchange sugar uptake in 
bEnd.3 cells. 
 Acute glucose depletion (15 minutes at 37ºC) also rapidly reduces bEnd.3 cell ATP 
content but only by 50%. This treatment increases Vmax for sugar uptake suggesting that 
sugar transport in blood-brain barrier endothelial cells is, like transport in cardiomyocytes 
and skeletal muscle, acutely sensitive to cellular metabolic status (179,221). AMP-
activated protein kinase (AMPK) is a key regulator of cellular metabolism. Upon 
elevation of cytoplasmic AMP levels, AMPK is phosphorylated and acts as a metabolic 
master switch, stimulating important metabolic processes such as fatty acid oxidation and 
glycolysis (180,181). Activated AMPK stimulates glycolysis in hypoxic cardiomyocytes 
and monocytes by activating 6-phosphofructo-2-kinase (179,202). Activated AMPK 
further supports increased anaerobic metabolism in heart and skeletal muscle by 
promoting recruitment of GLUT4 and GLUT1 to the cell membrane (203,222) thereby 
increasing sugar uptake and metabolism. 
 This mechanism may also be active in brain microvasculature endothelial cells 
because bEnd.3 cells acutely respond to metabolic poison, glucose-depletion and to the 
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AMPK agonist AICAR with increased AMPK phosphorylation as well as increased sugar 
transport rates. 
 Quantitative PCR and Western blot analyses of whole cell lysates show no significant 
changes in either GLUT1 mRNA levels or total protein expression in ATP-depleted cells. 
PCR data also indicates that GLUT1 appears to be the only GLUT isoform expressed at 
significant levels in bEnd.3 cells. Plasma membrane protein biotinylation studies show 
that GLUT1 levels are increased at the plasma membrane by 2-2.5 fold within ten 
minutes of treatment with either KCN or FCCP. These findings suggest that metabolic 
depletion of brain microvasculature endothelial cells results in AMPK activation, which 
in turn may induce net GLUT1 translocation to the cell membrane. 
 Immunoblot analysis of the GLUT1 content of bEnd.3 cell total lysates and 
streptavidin pull-downs of biotinylated membrane proteins indicates that two GLUT1 C-
terminal antibody reactive species are present: a minor 48 kDa protein and a more 
broadly mobile 55 kDa species. Both species collapse into a 42 kDa species upon 
treatment with the glycosidase PNGase F suggesting that each corresponds to a 
differentially glycosylated form of GLUT1. It is likely that the 42 kDa species seen in the 
PNGase F-treated cells represents the non-glycosylated form of GLUT1 that would be 
seen in the endoplasmic reticulum prior to modification by oligosaccharyltransferase. The 
48 kDa species, on the other hand, may potentially represent GLUT1 that is incompletely 
glycosylated but trafficked to the plasma membrane nonetheless, while the 55 kDa 
species represents the completely glycosylated form of GLUT1. Similar behavior is 
observed for human red cell GLUT1 (110,223) and rat brain microvascular endothelial 
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cells (224). Interestingly, cell surface levels of the 48 kDa species are unaffected by 
metabolic depletion whereas surface levels of the 55 kDa species are significantly 
increased giving rise to an approximate 2 to 3-fold increase in total cell surface GLUT1.  
 It is interesting to compare our findings using cultured bEnd.3 cells with transport 
studies in polarized endothelial cells. Rat blood-brain barrier glucose transport is acutely 
stimulated during seizure and immunohistochemical analysis suggests that this results 
from recruitment  of intracellular GLUT1 to both luminal and abluminal endothelial cell 
membranes (201). This being the case, our demonstration of GLUT1 recruitment in an 
unpolarized endothelial cell is not only representative of recruitment in a polarized bEND 
cell in vivo but may also uniquely provide the tools for detailed biochemical analysis of 
this phenomenon. 
 Earlier immunohistochemical analyses of GLUT1 expression in rat bEND cells in situ 
suggesting an asymmetric (1:4) distribution of GLUT1 between luminal and abluminal 
membranes (185,217) appear to be incorrect. Rather, GLUT1 is equally distributed 
between luminal and abluminal membranes (26). If stimulation of trans-capillary 
transport involves GLUT1 recruitment to luminal and abluminal endothelial membranes, 
polarized GLUT1 expression in bEND cells would significantly impact net transport 
stimulation. 
 Our analysis (13,23) indicates that starting from an equal distribution of carriers in 
luminal and abluminal membranes, increasing abluminal or luminal [GLUT1] in the 
absence of a commensurate increase at the trans-membrane would be without impact on 
net trans-endothelial cell sugar transport because the transport capacity of the membrane 
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containing the fewest number of transporters remains rate-limiting. Polarized GLUT1 
expression in the BBB endothelium only makes sense if one membrane (e.g. the luminal 
membrane) contains many more transporters than the abluminal membrane and 
regulation involves up-regulation at the abluminal membrane. The available evidence 
argues against this (26). 
    It has previously been shown that between 30-50% of GLUT1 resides in intracellular 
pools in endothelial cells (13,186). While this may partially explain the 2-3 fold increases 
in biotinylated GLUT1 seen during metabolic poisoning, it does not explain the 3-7 fold 
increases in Vmax for transport seen in the 3-OMG uptake measurements. Therefore, 
based on our analysis, there are two possible explanations for this increase: 1. the amount 
of intracellular GLUT1 has been underestimated and there is a much higher percentage of 
GLUT1 inside the cell than at the plasma membrane, or 2. the catalytic activity of 
GLUT1 is being modified to allow increased transport in addition to the translocation of 
GLUT1 to the plasma membrane. Further studies measuring the intracellular GLUT1 
content would give a clearer picture as to the distribution of GLUT1 under control and 
metabolically stressed conditions.  
    There are a number of steps in intracellular vesicular trafficking that require ATP to 
function. For example, the formation of clathrin-coated pits and the dissociation of 
clathrin from internalized vesicles are well known steps of endocytosis that require 
energy to function (225). Similarly, in exocytosis, steps such as the movement of vesicles 
along actin filaments and the disassociation of SNARE complexes are all ATP dependent 
processes (226,227). Therefore, it is safe to assume that severe ATP depletion of bEnd.3 
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cells by KCN and FCCP would effectively shut down intracellular trafficking. In order 
for GLUT1 to increase at the plasma membrane upon ATP depletion, its trafficking to the 
cell surface must be occurring rapidly in bEnd.3 cells before ATP is depleted too severely 
for trafficking to continue. Our data show that ATP depletion is occurring within 10-15 
minutes of exposure to poison, so GLUT1 translocation must also be occurring within 
this window. However, further studies are required to determine the time frame of 
GLUT1 trafficking after initial poison treatment, the amount of ATP depletion required 
to cause the translocation of GLUT1 to the plasma membrane, and the point at which 
ATP is too low for trafficking to continue. 
 In summary, acute metabolic depletion of murine bEnd.3 cells results in AMPK 
phosphorylation, GLUT1 recruitment to the cell membrane and increased sugar transport. 
This may allow endothelial cells to respond rapidly with increased blood-brain barrier 
sugar transport in locally hypoxic or metabolically-stressed regions of the brain. The 
exact nature of the involvement of AMPK in GLUT1 regulation in bEnd.3 cells requires 
further investigation. 
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CHAPTER IV 
AMP KINASE REGULATION OF SUGAR TRANSPORT IN BRAIN 
CAPILLARY ENDOTHELIAL CELLS DURING ACUTE METABOLIC STRESS 
Abstract 
    AMP-dependent kinase (AMPK) and GLUT1-mediated sugar transport in blood-brain 
barrier endothelial cells are activated during acute cellular metabolic stress. Using murine 
brain microvasculature endothelium bEnd.3 cells, we demonstrate that AMPK modulates 
endothelial cell glucose uptake by causing the net transfer of GLUT1 from intracellular 
pools to the plasma membrane. AMPK phosphorylation and stimulation of 3-O-
methylgucose transport by the AMPK agonist AICAR are inhibited in a dose-dependent 
manner by the AMPK antagonist Compound C.  Compound C also reduces AMPK 
phosphorylation and 3-O-methylgucose transport stimulation induced by cellular glucose-
depletion, by potassium cyanide (KCN) or by carbonyl cyanide-p-trifluoromethoxy-
phenylhydrazone (FCCP). Phosphorylation of the downstream AMPK-target, acetyl-CoA 
carboxylase, is blocked by Compound C. Cell-surface biotinylation studies reveal that 
plasma membrane GLUT1 levels are increased 2-3 fold by cellular glucose depletion, 
AICAR- or KCN-treatment, and that these increases are prevented by Compound C. 
These results support the hypothesis that AMPK activation in blood-brain barrier derived 
endothelial cells directs the trafficking of GLUT1 from intracellular pools to the plasma 
membrane, thereby increasing endothelial sugar transport capacity. 
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Introduction 
    The mammalian brain normally uses glucose as its primary energy source. While brain 
function and development require a constant glucose supply, diffusional exchange of 
glucose between blood and brain is severely restricted by the blood-brain barrier. This 
barrier comprises a non-fenestrated endothelium formed by capillary endothelial cells 
connected by tight junctions. Glucose that enters the brain must therefore cross the 
endothelium by protein-mediated trans-cellular transport. In the mammalian brain, this is 
catalyzed by the glucose transport protein GLUT1, which is expressed in luminal and 
abluminal membranes of endothelial cells and is essential for brain metabolic 
homeostasis (34,38,39,73,228). 
 Under resting conditions and at physiologic blood glucose levels, GLUT1-mediated 
glucose transport across the blood-brain barrier barely exceeds brain glucose utilization 
(13). When glucose consumption exceeds glucose supply, for example during 
hypoglycemia, hypoxia or intense neuronal activation, blood-brain barrier glucose 
transport responds by two different mechanisms. During chronic metabolic stress (e.g. 
hypoxia (194) and hypoglycemia (213,229)), GLUT1 gene and protein expression 
increase in vitro (215) and in vivo (216), thereby increasing blood-brain barrier sugar 
transport capacity. In contrast, acute metabolic stress (e.g. short-lived hypoglycemia, 
hypoxia, metabolic poisoning (187), or seizures (75,200)), is without effect on GLUT1 
expression but promotes recruitment of intracellular GLUT1 to the plasma membrane 
(186), thereby increasing blood-brain barrier sugar transport (230). The signals that 
regulate blood-brain barrier sugar transport during acute metabolic stress are not known.  
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    Phosphorylated AMP-activated kinase (AMPK) plays a key role in maintaining energy 
homeostasis in skeletal muscle (221,231), heart (202,232), brain (233,234), and 
endothelial cells (235) by switching cellular metabolism to lowered ATP consumption 
and increased ATP production. AMPK regulates glycolysis, fatty acid oxidation, and 
glucose transport (180,181,236). AMPK directs plasma membrane trafficking of GLUT1 
(222,237) and the insulin-sensitive glucose transporter GLUT4 in heart and muscle (238). 
    We recently demonstrated that several forms of acute metabolic stress, including 
glucose starvation, KCN or FCCP treatment, induce AMPK-phosphorylation (205) in the 
cultured brain microvascular endothelial cell line bEnd.3 (239). However, it is unclear 
whether AMPK activation is directly responsible for increased GLUT1-mediated sugar 
uptake. The results of the present study strongly suggest that AMPK directs the 
trafficking of GLUT1 between the endothelial cell membrane and intracellular pools, and 
thereby regulates blood-brain barrier endothelial cell sugar transport. 
Experimental Procedures 
Tissue Culture  
    bEnd.3 cells were obtained from ATCC and maintained in Dulbecco’s Modified Eagle 
Medium (DMEM) from Gibco supplemented with 10% fetal bovine serum (FBS) from 
Hyclone and 1% Penicillin/Streptomycin (Pen/Strep) solution (Gibco) at 37°C in a 
humidified 5% CO2 incubator as described previously (187).  
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Antibodies 
    A custom, affinity-purified rabbit polyclonal antibody raised against a synthetic 
peptide corresponding to GLUT1 amino acids 480-492 was produced by New England 
Peptide. Rabbit polyclonal and monoclonal antibodies against AMPK, phosphorylated 
AMPK (P-Thr172), ACC, and phosphorylated ACC (P-Ser-79) were obtained from Cell 
Signaling Technology. HRP conjugated Goat anti-rabbit secondary antibody was 
obtained from Jackson Immunoresearch.  
Buffers  
    Cell lysis buffer consisted of 5 mM HEPES, 5 mM MgCl2, 150 mM NaCl, 50 µM 
EDTA, and 1% SDS. Uptake stop solution included 10µM cytochalasin B (CCB, Sigma) 
and 100 µM phloretin (Sigma) in DPBS. TBS was composed of 20 mM Tris base and 
135 mM NaCl, pH 7.6. TBST comprised TBS buffer with 0.2% Tween-20. Biotin quench 
solution was composed of 250 mM Tris base. Biotin lysis buffer contained TBS with 
0.5% Triton-X-100.  
Western Blotting of bEnd.3 Cells 
    Confluent 100 mm dishes of bEnd.3 cells were treated with 2 mM AICAR 
(ThermoFisher) or 2 mM AICAR plus 1, 2, 5, 10, or 20 µM Compound C (Tocris 
Bioscience) for two hours; Cells were then washed twice with DPBS, lysed, and analyzed 
for total protein concentration using a micro BCA kit (Pierce). Western blots were 
performed as previously described (187) using a 1:1,000 dilution of either rabbit AMPK 
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P-Thr172 or rabbit ACC P-Ser 79 antibody. Samples were run in duplicate, and band 
densities were quantitated using ImageJ software. 
3-OMG Uptake Measurements in bEnd.3 cells 
    Uptake was measured for 30 sec at 4 ºC as previously described (187) using 20 mM 3-
O-methylglucose (3-OMG) containing 2.5 µCi/ml [3H]-3-O-methylglucose ([3H]-3-
OMG) in DPBS.  Sugar uptake measurements in AICAR-treated cells were performed as 
described above with the following modifications: on the day of the assay, cells were 
placed in serum-free DMEM or serum-free DMEM containing either 0 or 2 mM AICAR 
or 2 mM AICAR plus 1, 2, 10, or 20 µM Compound C for 2 hours at 37°C. Cells were 
washed with 1 ml of either glucose-free DPBS, DPBS containing 2 mM AICAR, or 
DPBS containing 2 mM AICAR plus Compound C, and sugar uptake was measured. 
    Sugar uptake in metabolically-poisoned and glucose-depleted cells was measured as 
described above with the following modifications: cells were placed in serum-free 
DMEM ± 10 µM Compound C, serum-free DMEM containing 2 mM AICAR ± 10 µM 
Compound C for 2 hours, or serum-free DMEM ± 10 µM Compound C for 1.5 hours 
followed by serum-free glucose-free DMEM ± 10 µM Compound C for 30 minutes. Cells 
were washed with 1 ml of either glucose-free DPBS, or glucose-free DPBS plus the 
appropriate poison (AICAR, KCN, or FCCP) ± 10 µM Compound C at which point 
uptake was measured.  
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Biotinylation of bEnd.3 cells 
    Biotinylation was carried out as previously described (187) with the following 
modifications: 150 cm2 plates of confluent bEnd.3 cells were placed in serum-free 
DMEM with 2 mM AICAR ± 10 µM Compound C for 2 hours, 2 mM AICAR ± 10 µM 
Compound C for 1.5 hours followed by serum-free, glucose-free DMEM ± 10 µM 
Compound C for 30 minutes, or 5 mM KCN ± 10 µM Compound C for 10 minutes at 
37°C prior to proceeding with biotinylation. 
Results 
Compound C Inhibits AICAR-dependent AMPK Phosphorylation 
    Phosphorylation of AMPK threonine 172 activates AMPK (181). In order to analyze 
Compound C inhibition of AMPK activity, we treated bEnd.3 cells with 2 mM AICAR to 
activate AMPK in the absence or presence of increasing concentrations of Compound C. 
Thr172 phosphorylation was analyzed by using an AMPK-phospho-Thr172-specific 
antibody (Figure 4.1A). AICAR-promoted AMPK phosphorylation decreases with 
increasing concentrations of Compound C and is suppressed at 10 µM inhibitor. Ki(app) 
(5.5 ± 2.2 µM) for inhibition of AMPK was computed by non-linear regression analysis 
of the concentration dependence of Compound C-inhibition of AICAR-dependent AMPK 
phosphorylation by assuming simple Michaelis-Menten inhibition (Figure 4.1B).  
    We also examined phosphorylation of acetyl co-A carboxylase (ACC), a direct 
downstream target of AMPK (239). Using an antibody specific to phosphorylated Ser79  
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Figure 4.1: Inhibition of AMPK Phosphorylation by Compound C 
Inhibition of AMPK by Compound C. A. Representative Western blot of whole cell 
bEnd.3 lysates in the absence or presence of AICAR and Compound C (concentrations 
indicated above the blots). Cell lysate (30 µg total protein) was loaded into each lane and 
probed with AMPK P-Thr 172 antibody. The mobility of molecular weight standards is 
indicated. B, Quantitation of Western blot band volumes from A and C respectively. 
Ordinate: relative band volume (%); Abscissa: Concentration of Compound C (µM).  
Data are shown for control cells (●) and AICAR-treated cells exposed to Compound C 
(■). Curves drawn though the Compound C data were computed by non-linear regression 
assuming simple competitive inhibition and provide Kiapp for Compound C inhibition of 
phosphorylation. Data points represent the mean ± S.E.M. for two separate experiments. 
 
B 
A 
Anti-AMPK P-Thr172 antibody 
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Figure 4.2: Inhibition of ACC Phosphorylation by Compound C 
A. Representative Western blot of whole cell bEnd.3 lysates in the absence or presence of 
AICAR and Compound C (concentrations indicated above the blots). Cell lysate (30 µg 
total protein) was loaded into each lane and probed with ACC P-Ser 79 antibody. The 
mobility of molecular weight standards is indicated. B. Quantitation of Western blot band 
volumes from A. Ordinate: relative band volume (%); Abscissa: Concentration of 
Compound C (µM).  Data are shown for control cells (●) and AICAR-treated cells 
exposed to Compound C (■). Curves drawn though the Compound C data were computed 
by non-linear regression assuming simple competitive inhibition and provide Kiapp for 
Compound C inhibition of phosphorylation. Data points represent the mean ± S.E.M. for 
two separate experiments. 
B 
A 
Anti-ACC P-Ser79 antibody 
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on ACC, we measured ACC phosphorylation in the presence of increasing [Compound 
C] (Figure 4.2A, 4.2B). Compound C reduces ACC phosphorylation in a dose-dependent  
manner with Ki(app) = 3.4 ± 1.2 µM. We also observe significant ACC phosphorylation in 
the absence of AICAR and Compound C, suggesting that basal AMPK activity is 
sufficient to phosphorylate ACC in untreated cells.  
Compound C Inhibits AICAR-stimulated 3-OMG Uptake 
    The facilitative glucose transport protein GLUT1 mediates sugar transport in control 
and AICAR-treated bEnd.3 cells, where AICAR increases Vmax for 3-OMG net uptake by 
2-fold (187). We therefore asked if AICAR-stimulation of transport is suppressed by 
Compound C.  
    bEnd.3 cells were treated with 2 mM AICAR plus increasing concentrations of 
compound C and uptake of 20 mM 3-OMG was measured over 30 seconds at 4ºC (Figure 
4.3). 3-OMG is a non-metabolizable GLUT1 substrate whose net uptake proceeds until 
intracellular [3-OMG] = extracellular [3-OMG] and unidirectional 3-OMG uptake and 
exit are quantitatively identical. Net uptake at 30 seconds achieves only 9 and 20% 
equilibration in control and FCCP-treated cells respectively (187), indicating that 
transport determinations at 30 sec underestimate steady-state transport rates by less than 
7%. In the present study, AICAR stimulates sugar uptake approximately 2.5-fold over 
control cells. Addition of Compound C inhibits bEnd.3 sugar uptake in a dose-dependent 
manner. Ki(app) for Compound C inhibition of AICAR-activated sugar uptake is 1.1 ± 0.2 
µM. The 95% confidence interval for Ki(app) for transport inhibition (0.1 - 2.1 µM)  
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Figure 4.3: Inhibition of Stimulation of Sugar Uptake by Compound C 
Sugar uptake at 4ºC in bEnd.3 Cells in Response to Compound C. 20 mM 3-OMG uptake 
was measured for 30 seconds in untreated cells (●) or in cells exposed 2 mM AICAR and 
increasing  [Compound C] (■) for 2 hours at 37ºC prior to cooling, glucose depletion and 
transport initiation. Ordinate: 3-OMG uptake (dpm per µg total cell protein); Abscissa: 
[Compound C] in µM. The curve drawn though the AICAR-treated cell data was 
computed by non-linear regression assuming simple saturable inhibition of uptake by 
Compound C but that uptake inhibition is incomplete. This permits calculation of Ki(app) 
for transport inhibition. Each point represents the mean ± S.E.M of three separate 
experiments. 
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overlaps with the confidence intervals for Ki(app) for Compound C  inhibition of AMPK 
phosphorylation (0 - 11 µM) and ACC phosphorylation (0.1 - 6.8 µM; Figures 4.1A, 
4.2A). Transport in the absence of AICAR is stimulated by Compound C, demonstrating 
that inhibition of AICAR-stimulated transport is not a direct action of the inhibitor on 
GLUT1. 
Compound C Inhibits AMPK Phosphorylation During Acute Metabolic Stress 
   AMPK phosphorylation increases, while total AMPK protein remains unchanged 
during acute metabolic stress (187). We therefore asked whether Compound C inhibits 
acute metabolic stress-induced AMPK activation in endothelial cells. We subjected 
bEnd.3 cells to AICAR treatment, glucose starvation (30 minutes), 5 mM KCN (10 
minutes), or 8µg/ml FCCP (10 minutes) in the absence or presence of Compound C, and 
assayed AMPK phosphorylation by Western blot. An untreated control was measured for 
basal AMPK phosphorylation (Figure 4.4A).  Quantitation of phosphorylation (Figure 
4.4B) indicates that all stress conditions and AICAR treatment increase AMPK 
phosphorylation by 4- to 10-fold. Cells treated only with Compound C show no 
significant increase in phosphorylation over controls. Compound C treatment causes 
stress-induced AMPK phosphorylation to decrease by 36% in glucose-starved cells, 56% 
in AICAR-treated cells, 69% in KCN-treated cells, and 61% in FCCP-treated cells. 
Although AMPK phosphorylation was reduced in the presence of Compound C, complete 
phosphorylation inhibition was not observed. 
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Figure 4.4: Inhibition of AMPK Phosphorylation During Stress 
Compound C inhibition of AMPK phosphorylation during metabolic stress. A. 
Representative Western blot of whole cell bEnd.3 lysates in the absence or presence of 
glucose, KCN, FCCP, AICAR and Compound C. Prior to lysis, cells were treated for 15 
min at 37 ºC with 5 mM glucose (control), 0 glucose, 5 mM KCN, 8 µg/mL FCCP or for 
2 hours with 2 mM AICAR in the absence or presence of 10 µM Compound C. Cell 
lysate (30 µg total protein) was loaded into each lane and probed with AMPK P-Thr 172 
antibody and band volumes were quantitated. B. Ordinate: relative band volume (%); 
Abscissa: experimental condition. Data represent the mean ± S.E.M of three separate 
experiments. 
B 
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Figure 4.5: Inhibition of Metabolic Stress-Stimulated Transport 
Compound C inhibition of stimulated 3-OMG uptake. Prior to cooling to 4ºC, glucose 
depletion and transport initiation, cells were treated for 15 min at 37 ºC with 5 mM 
glucose (control), 0 glucose, 5 mM KCN, 8 µg/mL FCCP or for 2 hours with 2 mM 
AICAR in the absence or presence of 10 µM Compound C. Uptake of 20 mM 3-OMG 
was then measured for 30 seconds in each condition. Ordinate: 3-OMG uptake (dpm per 
µg total cell protein). Abscissa: experimental condition. Data represent the mean ± S.E.M 
of three separate experiments. The symbol (*) represents a significant decrease in each 
data point versus its –Compound C control (p= 0.001). The symbol (§) represents a 
significant increase in each data point versus untreated control (p=0.000001). P values 
were obtained from a 1 tailed t-test assuming 2 sample equal variance. 
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Compound C Inhibits Metabolic Stress-Induced 3-OMG Uptake Stimulation 
    We next asked whether inhibition of AMPK phosphorylation suppresses sugar uptake 
stimulation during metabolic stress. 3-OMG uptake was measured in bEnd.3 cells in the 
absence and presence of 10 µM Compound C in cells that were glucose-starved, treated  
with 2 mM AICAR, treated with 5 mM KCN, or treated with 8µg/ml FCCP, as described 
above. 3-OMG uptake (Figure 4.5) is stimulated 2.6-fold in glucose starved cells, 2.6-
fold in AICAR treated cells, 2.9-fold in KCN treated cells, and 3.0-fold in FCCP treated. 
cells. Glucose transport in control cells is also stimulated 1.9-fold by 10 µM Compound 
C. Compound C inhibits 3-OMG uptake by 40% in glucose starved cells, 42% in AICAR 
treated cells, by 54% in KCN treated cells, and by 64% in FCCP treated cells (Figure 
4.5).   
Compound C Inhibition of GLUT1 Recruitment During Acute Metabolic Stress 
    bEnd.3 sugar transport stimulation during acute metabolic stress is mediated by 
recruitment of intracellular GLUT1 to the plasma membrane (187). The role of AMPK in 
mediating this process was evaluated by examining the effects of Compound C on 
GLUT1 recruitment. Cells were treated with 2 mM AICAR, glucose-starved or KCN-
treated as described above in the absence or presence of 10 µM Compound C. Cells were 
then washed, cooled to 4°C, and treated with the membrane-impermeant Sulfo-NHS-SS-
Biotin to label exposed primary amines (lysine side-chains). The reaction was quenched, 
the cells lysed in lysis buffer containing detergent, and biotinylated proteins were 
precipitated with streptavidin beads. Precipitated proteins were analyzed by Western blot  
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Figure 4.6: Inhibition of AMPK Induced GLUT1 Recruitment By Compound C 
Inhibition of plasma membrane GLUT1 recruitment by Compound C. A. Representative 
Western blot of cell surface biotinylated bEnd.3 cell proteins obtained in the absence and 
presence of 2 mM AICAR and 10 µM Compound C. Three C-terminal antibody-reactive 
species are observed with Mr(app) 42 kDa, 48 kDa, and 55 kDa, respectively. Cells were 
treated for 2 hours with AICAR at 37 ºC before cooling to 4 ºC and biotinylation. 80 µg 
of total protein was loaded into each lane and blotted with GLUT1 C-Ab. Band densities 
were quantitated as total, 48 kDa, and 55 kDa GLUT1 species and are shown in B. 
Ordinate: Relative band volume %. Abscissa: Experimental condition. Quantitations are 
shown as mean ± SEM of at least two experiments. 
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Figure 4.7: Inhibition of GLUT1 Recruitment Upon Glucose Depletion 
A. Representative Western blots of cell-surface biotinylated bEnd.3 cell proteins obtained 
in the absence and presence of 5 mM Glucose and 10 µM Compound C Three C-terminal 
antibody-reactive species are observed with Mr(app) 42 kDa, 48 kDa, and 55 kDa. Cells 
were glucose-depleted for 15 minutes at 37 ºC before cooling to 4 ºC and biotinylation. 
Total streptavidin-pull down protein (80 µg) was loaded into each lane and blotted with 
GLUT1 C-Ab. Band densities were quantitated as total, 48 kDa, and 55 kDa GLUT1 
species and are shown in B. Ordinate: Relative band volume %. Abscissa: Experimental 
condition. Each experiment was repeated at least twice and the results of quantitations are 
shown as mean ± SEM. 
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Figure 4.8: Inhibition of KCN Recruitment of GLUT1 by Compound C 
A. Representative Western blots of cell surface biotinylated bEnd.3 cell proteins obtained 
in the absence and presence of  5 mM KCN and 10 µM Compound C. Three C-terminal 
antibody-reactive species are observed with Mr(app) 42 kDa, 48 kDa, and 55 kDa. Cells 
were KCN-treated for 15 minutes at 37 ºC before cooling to 4 ºC and biotinylation. Total 
protein (80 µg) was loaded into each lane and blotted with GLUT1 C-Ab. Band densities 
were quantitated as total, 48 kDa, and 55 kDa GLUT1 species and are shown in B. 
Ordinate: Relative band volume %. Abscissa: Experimental condition. Each experiment 
was repeated at least twice and the results of quantitations are shown as mean ± SEM. 
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using anti-GLUT1 C-terminal IgGs (Figures 4.6A, 4.7A, and 4.8A) and band densities 
were quantitated (Figures 4.6B, 4.7B, and 4.8B). As recently reported (187), biotinylated, 
C-terminal-reactive GLUT1 is revealed as a 48 kDa species plus a broadly mobile 55 kDa 
species. Occasionally a 42 kDa species is also observed (Figures 4.7A, 4.8A). Treatment 
of membranes with peptide: N-glycosidase F causes all species to collapse to a 40-42 kDa 
GLUT1 species (187).  Cell-surface expression of the 48-kDa GLUT1 C-terminal 
antibody-reactive species is unchanged by AICAR or KCN, whereas expression of the 
55-kDa species is increased by 2–3-fold (Fig. 5, B and F). Glucose depletion appears to 
enhance cell-surface expression of the 48 and 55 kDa species by 4- and 2-fold, 
respectively. AICAR treatment increases total plasma membrane GLUT1 by 
approximately 2.1-fold, glucose depletion by approximately 3.0-fold, and KCN treatment 
by approximately 1.8-fold over controls. In contrast, Compound C-treated cells show no 
significant increase in plasma membrane GLUT1 (Figure 4.6B, 4.7B and 4.8B). These 
results mirror the increases in 3-OMG transport capacity produced by metabolic poisons.  
Discussion 
    This study examines the hypothesis that AMPK modulates GLUT1-mediated sugar 
uptake in brain microvascular endothelial cells by regulating plasma membrane GLUT1 
levels during acute metabolic stress. We show that endothelial cell AMPK is 
phosphorylated during metabolic stress and that this is inhibited in a dose-dependent 
manner by the AMPK antagonist, Compound C. AMPK activation by the AMPK agonist 
AICAR or by metabolic stress is associated with stimulation of GLUT1-mediated sugar 
uptake; but transport stimulation is inhibited in a dose-dependent manner by Compound 
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C. Transport stimulation appears to be caused by recruitment of intracellular GLUT1 to 
the cell surface, because Compound C blocks AICAR- and metabolic stress-induced 
GLUT1 recruitment. 
 Compound C is a high affinity ligand that competes with AMP and ATP for binding to 
AMPK (240). ATP- and Compound C-liganded AMPK are catalytically inactive but 
AMP-binding promotes AMPK phosphorylation, resulting in activation (180,181). ZMP, 
an AICAR metabolite, also binds at the AMP-binding site to activate the kinase 
(181,187). Compound C and ZMP-binding are thus mutually exclusive, thereby 
explaining Compound C-inhibition of AMPK activation by AICAR. Our studies confirm 
that AMPK phosphorylation in bEnd.3 cells is blocked by Compound C in a dose-
dependent manner. The observed Ki(app) (1 - 5 µM) is significantly greater than the 
reported Kd(app) (120 nM) for Compound C interaction with AMPK (241). This 
discrepancy most likely results from competition between Compound C and intracellular 
ZMP for binding to AMPK. At [ZMP] ≤ 2 mM and Kd(app) for ZMP binding to AMPK = 
90 µM (242), Ki(app) for Compound C inhibition of AMPK (KdCompound C 
(1+[ZMP]/KdZMP)) ≤ 2.8 µM. 
 Our previous work shows that acute metabolic stress induced by ATP depletion and 
mimicked by AICAR application to bEnd.3 cells increases sugar uptake and promotes 
AMPK phosphorylation (187). While a link between AMPK activation and sugar 
transport stimulation can be inferred, these findings do not establish causality. The 
present study demonstrates that AMPK activation and stimulation of sugar transport are 
both inhibited by the AMPK inhibitor Compound C.   
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    Compound C does not inhibit sugar transport directly. Rather, bEnd.3 cell 3-OMG 
uptake is stimulated 1.9-fold by Compound C. This may result from a well-characterized, 
independent regulatory mechanism (113,154,214,243-245) in which GLUT1-adenine 
nucleotide interactions allosterically modify sugar transport activity. ATP binding to 
GLUT1 reduces Vmax and Km for sugar uptake, while AMP displaces ATP from GLUT1, 
converting the protein to a high-capacity, low-affinity transporter. Compound C may 
compete with intracellular ATP for binding to GLUT1, thereby reversing allosteric 
inhibition of transport and increasing sugar uptake. It would be interesting to examine 
whether Compound C directly binds GLUT1 and can displace ATP and stimulate sugar 
uptake using a cell system without AMPK, such as red blood cells.  
    Stimulation of sugar uptake and AMPK phosphorylation by metabolic stress are 
significantly attenuated by Compound C. Cell-surface GLUT1 recruitment is completely 
blocked by Compound C. Phosphorylation of acetyl-CoA carboxylase (a GLUT1-
independent, AMPK downstream target (240)) is also inhibited by Compound C. These 
data, in conjunction with our previous findings (187), strengthen the hypothesis that 
AMPK-activation mediates bEnd.3 cell sugar transport stimulation during metabolic 
stress. Past studies have suggested that metabolic stress, and consequently AMPK, may 
play a role in changing the lipid environment in the plasma membrane, causing the 
masking and unmasking of glucose transporters at the cell surface (156,246). When 
GLUT1 resides in lipid raft domains, its accessibility and activity are limited. However, 
during times of metabolic stress, GLUT1 would move out of lipid raft domains via 
AMPK activity, thus increasing glucose uptake into the cell. This unmasking of GLUT1 
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could explain both the increased biotin labeling and increased GLUT1-mediated transport 
we saw in our studies. However, further studies have been done demonstrating that lipid 
rafts are an artifact of Triton-X100 treatment of biological membranes (247,248). 
Therefore, it is not feasible that AMPK modulation of lipid rafts is affecting GLUT1 
surface labeling by biotin, or its transport activity. 
 Chronic metabolic stress (hours to days) causes increased GLUT1 expression and 
increased sugar transport in brain microvascular endothelial cells 
(194,196,197,213,216,229). In contrast, acute metabolic stress (seconds to minutes) is 
without effect on GLUT1 expression, but increases cellular sugar transport capacity via 
recruitment of GLUT1 to the plasma membrane (187,200,201). The work presented here 
supports the hypothesis that AMPK modulates GLUT1 trafficking to the plasma 
membrane. AMPK-inhibition prevents stress-induced GLUT1 recruitment to the cell 
surface and ablates transport stimulation. AMPK is the primary sensor in cellular energy 
homeostasis (180,181), targeting and controlling numerous downstream processes such 
as gene expression and protein synthesis (249,250), glycolysis (179,251) and fatty acid 
oxidation (231,252,253). AMPK regulates GLUT1- and GLUT4-mediated sugar 
transport in muscle and adipose through control of gene expression or protein trafficking 
to the plasma membrane (237,238,250,254). AMPK therefore plays a dual role of 
initiating primary responses to acute changes in metabolic state and long-term responses 
to chronic alterations in cellular metabolism.  
    This dual role may be important in regulating the flow of metabolic substrates across 
the blood-brain barrier. Tight junctions connecting the endothelial cells of the blood-brain 
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barrier (255) prevent the diffusional exchange of small polar molecules between serum 
and brain. Metabolites needed for brain function must be transported across the 
endothelial cell barrier before they can be utilized (34-36,256). Glucose is a primary 
energy source for the brain and its transport across the blood-brain barrier is rate-limiting 
for brain glucose utilization under conditions of metabolic stress (13,23). When a region 
of the brain becomes significantly activated or when blood glucose levels fall, local 
blood-flow and glucose uptake are activated to maintain brain glucose availability 
(196,197,213,216,229,257). Our previous work (187) in combination with the present 
study reveal the underlying mechanism of blood-brain barrier sugar transport regulation 
during acute metabolic stress. Elevated intracellular AMP interacts with AMPK, causing 
AMPK phosphorylation and activation. Activated AMPK promotes the trafficking of 
intracellular GLUT1 to endothelial cell luminal and abluminal membranes, thereby 
enhancing glucose transport across the blood-brain barrier and glucose utilization by the 
brain. The downstream targets regulating GLUT1 trafficking and the trafficking steps 
(endocytosis, exocytosis) regulated by AMPK are unknown and warrant further study. 
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CHAPTER V 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
    It has long been assumed that increased glucose transport at the blood-brain barrier 
during acute metabolic stress is a result of increases in GLUT1 intrinsic activity, likely 
through loss of ATP binding to GLUT1 (155,214,243). Unlike chronic metabolic stress, 
acute stress has not been shown to increase GLUT1 expression (178,200). However, 
there have been few studies that have either confirmed this hypothesis or definitively 
characterized how glucose transport is increased during acute stress. The data presented 
in this thesis demonstrate a model for acute regulation of GLUT1-mediated sugar uptake 
in blood-brain barrier endothelial cells which is only in partial agreement with current 
assessments of acute stress effects on glucose transport. We have shown that GLUT1-
mediated uptake is increased within 10 minutes of ATP depletion through translocation 
of intracellular stores to the plasma membrane without increases in GLUT1 expression. 
We have also demonstrated that the AMP-dependent protein kinase AMPK is a key 
modulator of GLUT1 trafficking under conditions where ATP is rapidly depleted. 
    Perhaps one of the most pressing questions raised in studies of acute metabolic stress at 
the blood-brain barrier involves its relevance to in vivo metabolism. It could be argued 
that acute depletions of intracellular ATP are rare outside of individuals with metabolic 
disorders. Certainly, the cases of almost total ATP depletion seen in KCN and FCCP 
treated bEnd.3 cells are highly unlikely to occur unless the affected organism were 
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poisoned by these compounds. However, acute hypoglycemia can occur through a 
number of different means that are quite common to a variety of mammals, especially 
humans. Many patients with both type-1 and type-2 diabetes battle with acute 
hypoglycemia on a regular basis that results from poor blood sugar control and rapid 
insulin release into the bloodstream (258). In non-diabetics, sudden drops in blood 
glucose can be caused simply by exercise without sufficient food intake, particularly in 
athletes (259). The use of aspirin has long been known to decrease blood glucose, raising 
the potential for sudden hypoglycemia, especially if misused (260). In addition, the 
increase in anti-depressant prescriptions, particularly monoamine oxidase inhibitors 
(MAOI), has been prevalent in recent years. There is evidence that certain classes of 
these drugs can cause rapid decreases in blood glucose, especially if mixed with other 
medications and even certain foods (261). Therefore, our studies provide relevant insight 
into a regulatory mechanism that is necessary for maintaining brain function in a variety 
of pathological and normal physiological situations. Particularly, acute glucose 
deprivation of bEnd.3 cells, which only reduces ATP by only 50%, has the most 
relevance to the situations mentioned above. Admittedly, the complete, rapid depletion of 
intracellular ATP by KCN and FCCP in bEnd.3 cells is an extreme condition to study the 
acute stress response in bEnd.3 cells. However, studies using KCN and FCCP provide 
useful and relevant insight into the mechanisms of blood-brain barrier glucose transport 
regulation for many reasons. 
    The use of KCN and FCCP allow changes in ATP levels to be induced and visualized 
on a very short time scale without inducing apoptosis, as demonstrated by the KCN 
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washout experiments. Rapid ATP depletion means that glucose uptake can be measured 
after very short time points, which offers more accurate insight into how quickly 
endothelial cells are able to sense, and then respond to, perturbations in energy supply. In 
addition, both compounds affect ATP depletion and sugar uptake in a dose-dependent 
manner, allowing for more sensitive attenuation of the metabolic stress condition that 
simply cannot be achieved with glucose depletion. Finally, the use of KCN and FCCP 
allowed us to directly test the hypothesis that intrinsic changes in GLUT1 activity as a 
result of loss of ATP binding was the cause of increased GLUT1-mediated transport. 
Since ATP levels were depleted close to zero in KCN and FCCP-treated bEnd.3 cells, 
GLUT1-mediated transport would have increased without changes in protein expression 
or localization, and without interference of intracellular ATP. However, based on our 
findings, GLUT1 translocation to the plasma membrane appears to be the primary cause 
of increased glucose uptake in blood-brain barrier endothelial cells, with allosteric 
regulation by ATP only playing a minor role. Regardless of the severity of ATP depletion 
by KCN and FCCP, the transport and GLUT1 localization results are in agreement with 
the data generated from the much less drastic glucose starvation and AMPK stimulation 
experiments.  
    Translocation of GLUT1 to the plasma membrane in response to outside signals, while 
not unique to endothelial cells, does provide a dynamic adaptive mechanism for 
maintaining energy homeostasis. In most cases, increased GLUT1 at the plasma 
membrane resulting from growth factor or stress molecule signaling is caused by direct 
upregulation of GLUT1 expression. Increased GLUT1 synthesis leads to increased 
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cellular protein that eventually ends up at the plasma membrane (156,165,166,262). 
However, since approximately 50% of GLUT1 resides in intracellular pools at the blood-
brain barrier (186), by default, mobilization of those carriers to the plasma membrane 
would allow a doubling of transport capacity into the cell. Not only do our data support 
this view, but the rapid response to metabolic stresses is comparable to that seen in the 
insulin-response by GLUT4 in adipocytes. While the sugar uptake capacity in insulin-
responsive cells is much more dramatic, some similarities exist based on the rapid, 
reversible transport response to stress/insulin seen in bEnd.3 cells and insulin-sensitive 
tissue, respectively (263). The most striking difference in the bEnd.3 response to acute 
metabolic stress is that, unlike in insulin stimulated cells, GLUT1 trafficking to the 
plasma membrane is not a result of increased constitutive recycling, as evidenced by the 
lack of Na+K+ATPase recruitment upon acute stress. Instead, it would appear that 
regulation of GLUT1 trafficking is via a more specific mechanism that allows for its 
rapid recruitment to the plasma membrane in response to decreasing ATP. 
    AMPK has long been considered the master switch in maintaining cellular metabolic 
homeostasis in cells. Its ability to increase fatty acid oxidation, glycolysis, and glucose 
uptake and decrease lipogenesis, gluconeogenesis, and glycogen synthesis are well 
documented in a variety of tissue types (181,236). As a result, there are a number of 
downstream targets for AMPK that allow it to control everything from protein synthesis 
and gene expression to protein trafficking. Its activity is tied directly to AMP binding its 
catalytic α subunit, inducing phosphorylation and activation of the enzyme, so it should 
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be no surprise that increased AMP generated by ATP depletion through glucose 
starvation and KCN or FCCP treatment would activate AMPK in bEnd.3 cells. All of 
these stresses were shown to activate AMPK, and specific inhibition of AMPK by 
Compound C ablates its phosphorylation, regardless of the stress condition monitored. In 
addition, AMPK activation through the agonist AICAR, as well as activation through 
metabolic stress, increases GLUT1-mediated sugar uptake and recruitment to the plasma 
membrane. What is surprising and unique is that Compound C inactivation of AMPK 
ablates both stimulation of sugar uptake and GLUT1 recruitment to the plasma 
membrane, regardless of the stress condition tested. This indicates that AMPK activation 
is both necessary and sufficient for increased GLUT1-mediated transport and GLUT1 
translocation to the plasma membrane. It will be important to confirm these results by 
knocking down AMPK in bEnd.3 cells to eliminate the possibility of non-specific side 
effects from Compound C treatment. Although there are a number of other stress-
activated signaling molecules that can regulate GLUT1-mediated transport, such as p38 
and ERK1/2, based on our studies it would appear that they play little to no role in 
regulation of endothelial cell glucose transport during acute stress (264,265).   
    HIF1α is also a known regulator of GLUT1-mediated transport, and is primarily 
responsible for the upregulation of GLUT1 expression seen at the blood-brain barrier 
during chronic stress (177,178). Interestingly, HIF1α is also a downstream target of 
AMPK, which can be regulated through the mTOR signaling pathway (266). Therefore, it 
is possible that HIF1α could be a downstream modulator of AMPK’s effect on GLUT1 
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during acute metabolic stress. Based on our preliminary studies, no conclusions can be 
drawn about HIF1α and its role as a downstream target of AMPK regulation of bEnd.3 
cell glucose transport. However, future studies could be performed to assess the role 
HIF1α plays in regulating bEnd.3 GLUT1 during metabolic stress. 
    Changes in GLUT1 trafficking to the plasma membrane can occur by three possible 
mechanisms: changes in endocytosis, changes in exocytosis, or changes in both 
processes. The increased cell surface GLUT1 seen in bEnd.3 cells could arise from either 
a decrease in endocytosis, an increase in exocytosis, or a combination of the two during 
metabolic stress. Since AMPK is involved in regulating GLUT1 trafficking in bEnd.3 
cells, considerations should be made as to its mode of action on GLUT1 recycling, even 
thought AMPK does not directly phosphorylate GLUT1 itself (150). Studies in muscle 
cells have shown that AMPK activation can induce an increase in GLUT4-mediated 
sugar uptake that is insulin independent. Furthermore, stimulation of these cells with 
insulin in conjunction with activation of AMPK shows additive increases to GLUT4-
mediated glucose uptake. It has been shown that insulin primarily regulates GLUT4 
trafficking by accelerating exocytosis of the protein to the plasma membrane. However, 
AMPK activity in insulin-sensitive cells has the opposite effect, decreasing endocytosis 
of GLUT4 from the plasma membrane. Thus, the addition of both stimuli causes an 
increase in exocytosis, a decrease in endocytosis, and an additive increase in GLUT4-
mediated sugar uptake (267). In terms of GLUT1, AMPK’s activity in insulin-sensitive 
muscle cells may give insight into its mode of action in bEnd.3 cells. Based on these 
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studies, GLUT1 recruitment to the plasma membrane could be a result of AMPK-
decreased endocytosis. Certainly, AMPK activation has a direct effect on GLUT1 
trafficking. However, further study is needed to determine which aspects of trafficking 
are regulated by AMPK and through which pathway, since PKC and PI3K have both 
been shown to control GLUT1 translocation to the plasma membrane in a variety of cell 
types, including insulin-sensitive tissue (166,268). In addition, there could be other as yet 
unknown factors that regulate GLUT1 trafficking. For example, it is possible that GLUT1 
trafficking could be directed based on the whether ATP or AMP is bound to the 
transporter. If ATP is bound to GLUT1, then energy supplies in the cell are high, so 
higher levels of transporter are unnecessary at the plasma membrane. As a result, GLUT1 
may be directed to reside inside the cell. In contrast, when ATP drops and AMP binds 
GLUT1, it is possible that some factor (possibly AMPK or a downstream target) could 
recognize AMP-GLUT1 and induce translocation to the plasma membrane. Although 
there is no data to currently support this model, it is possible that the nucleotide bound to 
GLUT1 may play a role in not only its transport activity, but its localization. While there 
are also a few potential downstream targets to investigate, such as HIF1α, many of the 
signaling factors involved in GLUT1 trafficking, and protein trafficking in general, 
remain elusive at this time. Therefore, much work needs to be done to identify and 
characterize these targets in the context of modulation of endothelial cell glucose 
transport. Our attempts to measure the changes to GLUT1 endocytosis and exocytosis 
have thus far been unsuccessful. However, transfection of a tagged GLUT1 construct 
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could provide useful information about changes in GLUT1 localization, as well as 
changes in the kinetics of internalization and externalization during metabolic stress.  
    When considering GLUT1-mediated transport at the blood-brain barrier, the role of the 
brain in regulating endothelial cell transport must be included. While our data suggest 
that the blood-brain barrier is able to sense and respond to changes in energy levels 
through the activity of AMPK, it remains a possibility that the brain itself would play a 
role in maintaining its own energy supply. Intracellular glucose concentration in neurons 
and astrocytes tends to be lower than endothelial glucose, even under normal metabolic 
conditions (13). Therefore, decreases in glucose supply across the blood-brain barrier 
would also be sensed by neurons and astrocytes rather quickly. There is evidence to 
suggest that astrocyte-endothelial cell communication is a common phenomenon at the 
blood-brain barrier. Astrocyte feet rest on the blood vessels comprising the endothelium, 
so cell-to-cell signaling could be achieved relatively quickly and easily. It has been 
shown that astrocytes are able to rapidly communicate with neurons and each other, 
increasing glucose transport during metabolic activity (20,269). In addition, two-way 
communication between astrocytes and the blood-brain barrier have been shown to affect 
both astrocyte differentiation and blood-brain barrier permeability (270). However, what 
is most interesting is that astrocytes have not only been shown to induce blood-brain 
barrier-like properties in non blood-brain barrier endothelial cells when co-cultured, but 
chronically glucose-deprived astrocytes can influence glucose transporter expression and 
glucose uptake in brain microvessels (257,271,272). These studies indicate that there is a 
mechanism for brain-endothelial communication, but the factors involved in coordinating 
130 
 
glucose uptake across the blood-brain barrier are unclear. It is possible that ATP 
depletion could lead to activation of AMPK in neurons, astrocytes, or both. This 
activation of AMPK could also activate GLUT1-mediated transport at the blood-brain 
barrier through a secretory signaling mechanism. Furthermore, the studies on brain-
endothelial communication give no insight as to how rapid changes in energy affect brain 
metabolism. It is possible that brain cells respond in a similar manner to blood-brain 
barrier endothelial cells, though there is no evidence to date in support of this. Perhaps 
the endothelium is responsible for maintaining brain glucose homeostasis during acute 
stress, while brain cells are able to induce the blood-brain barrier to increase transport 
capacity under more chronic stress conditions. Unfortunately, our studies have not 
provided sufficient data at this time to reach any such conclusions, but it is clear that 
there is much to be learned about regulation of glucose uptake by the brain. 
    In conclusion, the data presented in this thesis provide a preliminary model for how 
blood-brain barrier endothelial cell glucose transport is modulated during acute metabolic 
stress. There have been numerous studies demonstrating the changes to localized cerebral 
blood flow during times of metabolic stress and brain injury (14-16). It has been 
presumed that increased blood flow allows the delivery of essential metabolites to the 
area under stress, most importantly glucose and oxygen. However, without a mechanism 
to accommodate this localized influx of nutrients, the extra volume of blood would do no 
good due to the impermeability of the blood-brain barrier. Our studies have further 
defined the mechanism of how the blood-brain barrier endothelial cells may respond to 
metabolic stress by rapidly increasing local glucose transport capacity as needed. During 
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metabolic stress, AMPK is activated, causing translocation of intracellular GLUT1 to the 
plasma membrane. By increasing GLUT1 at the endothelial cell surface, the blood-brain 
barrier is at least doubling the capacity for glucose uptake into the brain, providing much 
needed metabolic substrate during times when acute stress leaves energy demand high or 
energy supply low. Thus, by exerting localized control over both the vasculature and 
endothelium, the brain is able to regulate glucose supplies in order to compensate for 
rapid changes in its metabolic state, ensuring continued function and survival of the organ 
and organism. 
    While it is clear that GLUT1 translocation, mediated by AMPK, is responsible for 
increased glucose transport rate, there are a number of questions that still remain as a 
result of this work. For example: what are some of the other downstream signaling 
factors that modulate GLUT1 trafficking through AMPK? Do these unknown factors 
regulate GLUT1 endocytosis, exocytosis, or both? Is this trafficking effect truly GLUT1-
specific, or are there other proteins that follow the same pathway? What is the role of 
neurons and astrocytes in modulating endothelial GLUT1 during acute stress, if any? 
Does acute metabolic stress in brain cells produce the same effect on transport at the 
blood-brain barrier? Seeking the answers to these questions will not only provide the 
groundwork for many future studies, but will contribute significantly to a more complete 
understanding of how the brain, and the barrier that protects it, modulate glucose uptake 
and energy homeostasis. 
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